About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
Empagliflozin
- Company
- Boehringer Ingelheim
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 90 recruiting
Efficacy results: Not yet reported
90 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026
Find a Clinical Trial Near Me
See recruiting studies for Empagliflozin and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT03424005
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Not yet reported, Not yet reported Hoffmann-La Roche 1132 participants Est. completion 2030-09-30 53 sites Stand-aloneOther conditions: Metastatic Breast CancerView official trial listing → -
Recruiting NCT NCT03878706
The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
University of Athens 240 participants Est. completion 2027-06-30 1 siteType 2 diabetesView official trial listing → -
Recruiting NCT NCT04381936
Randomised Evaluation of COVID-19 Therapy
Not yet reported University of Oxford 70000 participants Est. completion 2038-09-30 16 sitesOther conditions: PneumoniaView official trial listing → -
Recruiting NCT NCT04447911
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia
Not yet reported University Hospital, Basel, Switzerland 113 participants Est. completion 2026-09-15 6 sites Stand-aloneOther conditions: Hyponatremia, SIADH, Liver Failure, Kidney FailureView official trial listing → -
Recruiting NCT NCT04602754
Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
Not yet reported EMS 228 participants Est. completion 2027-09 1 site Stand-aloneOther conditions: Dyslipidemia Associated With Type II Diabetes MellitusView official trial listing → -
Recruiting NCT NCT04662723
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
Not yet reported Fondazione Schena 878 participants Est. completion 2028-12-31 2 sitesOther conditions: Glomerulonephritis, Immunoglobulin A NephropathyView official trial listing → -
Recruiting NCT NCT04670666
Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus
Not yet reported EMS 270 participants Est. completion 2027-06 1 site Stand-aloneType 2 diabetesView official trial listing → -
Recruiting NCT NCT05028140
Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus
Not yet reported EMS 480 participants Est. completion 2027-09 1 site Stand-aloneOther conditions: Type II DiabetesView official trial listing → -
Recruiting NCT NCT05164263
Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study
Not yet reported Getz Pharma 2000 participants Est. completion 2027-08-31 6 sites Stand-aloneOther conditions: Type II Diabetes Mellitus, Efficacy, Self, Safety IssuesView official trial listing → -
Recruiting NCT NCT05390892
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Not yet reported Brigham and Women's Hospital 6000 participants Est. completion 2029-03-01 36 sitesCardiovascular disease Other conditions: Type2DiabetesView official trial listing → -
Recruiting NCT NCT05669742
Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients
Not yet reported Tanta University 40 participants Est. completion 2026-12 1 siteOther conditions: Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by AntipsychoticsView official trial listing → -
Recruiting NCT NCT05715814
meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
Not yet reported University Health Network, Toronto 20 participants Est. completion 2027-12-01 1 site Stand-aloneOther conditions: Peritoneal Dialysis Complication, End Stage Kidney Disease, Sodium-glucose Co-transporter-2 Inhibitors, Kidney Dysfunction, Residual Kidney FunctionView official trial listing → -
Recruiting NCT NCT05726032
Empagliflozin in Patients With Cirrhosis and Ascites
Not yet reported Yale University 20 participants Est. completion 2026-12-01 1 siteOther conditions: Cirrhosis, Liver FailureView official trial listing → -
Recruiting NCT NCT05770687
SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
Kiyuk Chang 1000 participants Est. completion 2026-12-31 1 siteCardiovascular diseaseType 2 diabetesView official trial listing → -
Recruiting NCT NCT05786443
Safety and Efficacy of Empagliflozin in Hemodialysis
Not yet reported NYU Langone Health 60 participants Est. completion 2026-12-30 2 sites Stand-aloneOther conditions: End Stage Renal DiseaseView official trial listing → -
Recruiting NCT NCT05879276
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
Not yet reported Central Hospital, Nancy, France 164 participants Est. completion 2027-03-16 8 sites Stand-aloneOther conditions: Cardiogenic ShockView official trial listing → -
Recruiting NCT NCT05960656
SGLTi, Hepatic Glucose Production and Ketogenesis
Not yet reported The University of Texas Health Science Center at San Antonio 30 participants Est. completion 2027-06-30 1 site Stand-aloneType 2 diabetesView official trial listing → -
Recruiting NCT NCT06013865
Empagliflozin Treatment in Kidney Transplant Recipients
Not yet reported VA Office of Research and Development 264 participants Est. completion 2030-03-31 5 sitesChronic kidney disease Other conditions: Kidney TransplantView official trial listing → -
Recruiting NCT NCT06024746
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Not yet reported Colorado Prevention Center 1500 participants Est. completion 2027-11 140 sites Stand-aloneHeart failureView official trial listing → -
Recruiting NCT NCT06055452
Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
Not yet reported China National Center for Cardiovascular Diseases 120 participants Est. completion 2026-12-31 2 sites Stand-aloneHeart failure Other conditions: HypertensionView official trial listing → -
Recruiting NCT NCT06091475
Therapy to Maintain Remission in Dilated Cardiomyopathy
Not yet reported Imperial College London 50 participants Est. completion 2026-09-15 1 site Stand-aloneHeart failure Other conditions: Cardiomyopathy, Dilated, Cardiomyopathies, Heart DiseasesView official trial listing → -
Recruiting NCT NCT06095492
Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus
Not yet reported Medanta, The Medicity, India 200 participants Est. completion 2025-12-01 1 site Stand-aloneOther conditions: Kidney Transplant; Complications, Diabetes MellitusView official trial listing → -
Recruiting NCT NCT06110130
Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
Not yet reported Washington D.C. Veterans Affairs Medical Center 60 participants Est. completion 2028-12-01 1 siteChronic kidney diseaseView official trial listing → -
Recruiting NCT NCT06142474
SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning
Not yet reported National Taiwan University Hospital 450 participants Est. completion 2030-10-09 1 site Stand-aloneHeart failure Other conditions: Ventilator LungView official trial listing → -
Recruiting NCT NCT06143566
Polypill for Prevention of Cardiomyopathy
Not yet reported, Not yet reported University of Texas Southwestern Medical Center 200 participants Est. completion 2027-12-01 1 site Stand-aloneType 2 diabetes Other conditions: High Blood PressureView official trial listing → -
Recruiting NCT NCT06229678
Ketones, SGLT2, HFrEF
Not yet reported The University of Texas Health Science Center at San Antonio 71 participants Est. completion 2027-03-01 1 site Stand-aloneHeart failure Other conditions: Type2diabetesView official trial listing → -
Recruiting NCT NCT06249932
Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease
Not yet reported National Taiwan University Hospital 95 participants Est. completion 2030-12-31 2 sites Stand-aloneHeart failure Other conditions: End Stage Renal Disease on DialysisView official trial listing → -
Recruiting NCT NCT06249945
EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
Not yet reported National Taiwan University Hospital 150 participants Est. completion 2030-12-31 2 sites Stand-aloneHeart failure Other conditions: End Stage Renal Disease on DialysisView official trial listing → -
Recruiting NCT NCT06260059
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
Not yet reported Anita Saraf 40 participants Est. completion 2027-06-01 3 sites Stand-aloneHeart failure Other conditions: Adult Congenital Heart DiseaseView official trial listing → -
Recruiting NCT NCT06355310
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
Not yet reported Justin Ryder 40 participants Est. completion 2028-02-01 1 site Stand-aloneOther conditions: Non-Alcoholic Fatty Liver DiseaseView official trial listing → -
Recruiting NCT NCT06410352
Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
Not yet reported University Medical Center, Kazakhstan 220 participants Est. completion 2026-07-31 1 siteMetabolic syndromeView official trial listing → -
Recruiting NCT NCT06424288
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Not yet reported Boehringer Ingelheim 6000 participants Est. completion 2028-05-22 652 sites Stand-aloneHeart failureView official trial listing → -
Recruiting NCT NCT06430684
Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease
Not yet reported Ann & Robert H Lurie Children's Hospital of Chicago 40 participants Est. completion 2026-11-01 1 site Stand-aloneChronic kidney disease Other conditions: Pediatric Kidney DiseaseView official trial listing → -
Recruiting NCT NCT06435858
Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
Not yet reported Cantonal Hospital Graubuenden 40 participants Est. completion 2025-10 2 sites Stand-aloneOther conditions: Autosomal Dominant Polycystic Kidney DiseaseView official trial listing → -
Recruiting NCT NCT06446531
Prevention of Progression of Prediabetes, Obesity and CV Risk
Not yet reported The University of Texas Health Science Center at San Antonio 64 participants Est. completion 2027-07 1 site Stand-alonePrediabetesCardiovascular disease Other conditions: Weight, BodyView official trial listing → -
Recruiting NCT NCT06483074
Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients
Not yet reported Chinese University of Hong Kong 48 participants Est. completion 2026-10-31 1 siteOther conditions: End Stage Renal Disease on Dialysis, Peritoneal Dialysis Complication, Sodium-glucose Cotransporter-2 Inhibitor, Residual Kidney FunctionView official trial listing → -
Recruiting NCT NCT06506422
Empagliflozin Reversal of Arterial StiffnEss in Aging
Not yet reported, Not yet reported University of Missouri-Columbia 80 participants Est. completion 2029-02-28 1 site Stand-aloneOther conditions: Aging, Arterial StiffnessView official trial listing → -
Recruiting NCT NCT06531824
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Not yet reported Boehringer Ingelheim 11000 participants Est. completion 2028-08-30 520 sites Stand-aloneOther conditions: Kidney Disease, ChronicView official trial listing → -
Recruiting NCT NCT06554301
A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension
Not yet reported China National Center for Cardiovascular Diseases 72 participants Est. completion 2026-12 1 site Stand-aloneOther conditions: Pulmonary Arterial HypertensionView official trial listing → -
Recruiting NCT NCT06585761
Effect of Sodium Glucose Co-tansporter 2 Inhibitors (SGLT2I) on Inflammatory and Oxidative Stress Markers Level in Heart Failure Patients
Kafrelsheikh University 60 participants Est. completion 2025-06-30 1 siteHeart failureView official trial listing → -
Recruiting NCT NCT06609356
Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes
Not yet reported Vanderbilt University Medical Center 27 participants Est. completion 2027-12 1 siteOther conditions: Type 1 Diabetes Mellitus, Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), MODY2 Diabetes, Healthy VolunteerView official trial listing → -
Recruiting NCT NCT06625073
Randomized Trial of SGLT2i in Heart Transplant Recipients
Not yet reported VA Office of Research and Development 200 participants Est. completion 2030-02-28 6 sites Stand-aloneCardiovascular disease Other conditions: Heart Transplant, Kidney DiseaseView official trial listing → -
Recruiting NCT NCT06642272
A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
Not yet reported Herlev and Gentofte Hospital 17200 participants Est. completion 2028-12-31 12 sitesType 2 diabetesHeart failureChronic kidney diseaseView official trial listing → -
Recruiting NCT NCT06642623
A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus Patients
Not yet reported Yonsei University 2862 participants Est. completion 2030-12-31 1 siteType 2 diabetesCardiovascular disease Other conditions: Kidney DiseasesView official trial listing → -
Recruiting NCT NCT06653738
Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention
Not yet reported Insel Gruppe AG, University Hospital Bern 400 participants Est. completion 2030-09 21 sites Stand-aloneOther conditions: Kidney Stone, Nephrolithiasis, Dietary ExposureView official trial listing → -
Recruiting NCT NCT06655480
Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF
Not yet reported National Medical Research Center for Cardiology, Ministry of Health of Russian Federation 50 participants Est. completion 2027-12-31 1 site Stand-aloneHeart failure Other conditions: LVDD, Myocardial FibrosisView official trial listing → -
Recruiting NCT NCT06674109
SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial
Not yet reported Massachusetts General Hospital 60 participants Est. completion 2028-02-28 1 site Stand-aloneOther conditions: Gout and HyperuricemiaView official trial listing → -
Recruiting NCT NCT06706791
Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II
Not yet reported Fazaia Ruth Pfau Medical College 156 participants Est. completion 2026-12-01 1 site Stand-aloneHeart failureView official trial listing → -
Recruiting NCT NCT06715449
EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source
Not yet reported, Not yet reported University of East Anglia 100 participants Est. completion 2029-03 1 site Stand-aloneCardiovascular disease Other conditions: Atrial Fibrillation New OnsetView official trial listing → -
Recruiting NCT NCT06753994
Continuous Ketone Monitoring in People With Type 1 Diabetes Using SGLT2 Inhibitors
Not yet reported McGill University 24 participants Est. completion 2027-01-01 1 site Stand-aloneOther conditions: Diabetes, Type1diabetes, T1DView official trial listing → -
Recruiting NCT NCT06821919
Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps)
Western Galilee Hospital-Nahariya 70 participants Est. completion 2031-12-30 1 siteOther conditions: Diabetes Mellitus, Kidney DiseaseView official trial listing → -
Recruiting NCT NCT06843902
Improving Coronary Vascular Health in Women
Not yet reported Massachusetts General Hospital 80 participants Est. completion 2029-06 1 site Stand-aloneOther conditions: HIV-1-infection, Coronary Microvascular Dysfunction, Metabolic DiseaseView official trial listing → -
Recruiting NCT NCT06846411
The EMPA-FIT Study
Not yet reported Seoul National University Bundang Hospital 46 participants Est. completion 2025-12-31 1 site Stand-aloneOther conditions: Diabetes, Diabetes Mellitus, Type IIView official trial listing → -
Recruiting NCT NCT06862739
Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
Not yet reported Nabiqasim Industries (Pvt) Ltd 800 participants Est. completion 2026-06-30 2 sitesOther conditions: Diabetes Mellitus, Type 2 DMView official trial listing → -
Recruiting NCT NCT06894784
A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes
Not yet reported McGill University Health Centre/Research Institute of the McGill University Health Centre 36 participants Est. completion 2027-01 1 site Added to GLP-1Other conditions: Diabetes Type 1View official trial listing → -
Recruiting NCT NCT06929169
Cardiovascular Effects of SGLT2 Inhibitors in Hemodialysis Patients: A Phase 2 Randomized Study
Not yet reported Maximo Agustin Schiavone 80 participants Est. completion 2026-08 1 site Stand-aloneChronic kidney diseaseView official trial listing → -
Recruiting NCT NCT06930092
RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy
Not yet reported Seoul National University Hospital 158 participants Est. completion 2029-04-30 1 siteOther conditions: Ischemic CardiomyopathyView official trial listing → -
Recruiting NCT NCT06935370
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Not yet reported Boehringer Ingelheim 4200 participants Est. completion 2029-02-22 588 sites Stand-aloneHeart failureView official trial listing → -
Recruiting NCT NCT06992440
Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
Not yet reported Gustavo A Heresi, MD, MS 78 participants Est. completion 2030-09 3 sitesOther conditions: Pulmonary Arterial HypertensionView official trial listing → -
Recruiting NCT NCT07023172
Multicenter, Prospective, Observational Study on the Treatment of Type 2 Diabetes With Proline Plus Empagliflozin Tablets
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 3000 participants Est. completion 2027-10 2 sitesType 2 diabetesView official trial listing → -
Recruiting NCT NCT07038356
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
Not yet reported Christian Schulze 536 participants Est. completion 2027-06-30 12 sitesHeart failureView official trial listing → -
Recruiting NCT NCT07053293
SGLT2i, Hepatic Glucose Production, and SNS
Not yet reported The University of Texas Health Science Center at San Antonio 22 participants Est. completion 2027-06-30 1 site Stand-aloneType 2 diabetesView official trial listing → -
Recruiting NCT NCT07053306
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
Not yet reported The University of Texas Health Science Center at San Antonio 29 participants Est. completion 2027-06-30 1 site Stand-aloneType 2 diabetesView official trial listing → -
Recruiting NCT NCT07053319
SGLT2i, Pioglitazone, and Ketone Production in T2D
Not yet reported The University of Texas Health Science Center at San Antonio 64 participants Est. completion 2027-06-30 1 site Stand-aloneType 2 diabetesView official trial listing → -
Recruiting NCT NCT07055282
SGLT2i in Kidney Stones
Not yet reported University of Chicago 32 participants Est. completion 2028-11-01 1 siteOther conditions: Kidney StonesView official trial listing → -
Recruiting NCT NCT07064473
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Not yet reported Boehringer Ingelheim 11800 participants Est. completion 2029-12-21 1143 sites Stand-aloneType 2 diabetesCardiovascular disease Other conditions: HypertensionView official trial listing → -
Recruiting NCT NCT07093476
Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin
Not yet reported Celltrion 171 participants Est. completion 2027-04 1 siteType 2 diabetes Other conditions: Diabete Type 2, DMView official trial listing → -
Recruiting NCT NCT07107945
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
Not yet reported Boehringer Ingelheim 120 participants Est. completion 2028-04-14 93 sites Stand-aloneChronic kidney diseaseView official trial listing → -
Recruiting NCT NCT07141355
Empagliflozin's Microcirculatory Effects in Cardiogenic Shock: an Ancillary Pilot Study of the EMPASHOCK Trial
Not yet reported University Hospital, Strasbourg, France 24 participants Est. completion 2027-09-30 1 siteOther conditions: Cardiogenic ShockView official trial listing → -
Recruiting NCT NCT07157475
Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
Wroclaw Medical University 300 participants Est. completion 2026-12-31 1 siteOther conditions: Peripheral Arterial Disease(PAD)View official trial listing → -
Recruiting NCT NCT07214818
SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
Not yet reported, Not yet reported Mansoura University 75 participants Est. completion 2026-09-06 1 site Stand-aloneOther conditions: Nephrotic SyndromeView official trial listing → -
Recruiting NCT NCT07228195
SGLT2i Therapy in Islet Transplantation (SIT)
Not yet reported University of Minnesota 40 participants Est. completion 2028-12-01 1 siteOther conditions: Partial Islet Function, TPIAT, DiabetesView official trial listing → -
Recruiting NCT NCT07231939
Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
Collegium Medicum w Bydgoszczy 4000 participants Est. completion 2026-03-31 1 siteCardiovascular disease Other conditions: Acute Kidney Injury, Contrast-Induced Acute Kidney Injury, Percutaneous Coronary InterventionView official trial listing → -
Recruiting NCT NCT07292909
Effect of Empagliflozin on Inflammation
Not yet reported Hotel Dieu de France Hospital 100 participants Est. completion 2027-09-30 1 siteCardiovascular disease Other conditions: Inflamation, PCI, SGLT 2 InhibitorsView official trial listing → -
Recruiting NCT NCT07304817
Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)
Not yet reported University Medical Center Groningen 100 participants Est. completion 2028-02 2 sites Stand-aloneChronic kidney diseaseCardiovascular diseaseHeart failureView official trial listing → -
Recruiting NCT NCT07309094
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Cardenal Herrera University 250 participants Est. completion 2028-12-31 1 siteChronic kidney diseaseType 2 diabetes Other conditions: ObesityView official trial listing → -
Recruiting NCT NCT07322237
DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
Not yet reported Post Graduate Institute of Medical Education and Research, Chandigarh 400 participants Est. completion 2029-06-30 1 siteOther conditions: Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors, CirrhosisView official trial listing → -
Recruiting NCT NCT07331389
A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
Not yet reported Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. 111 participants Est. completion 2026-06-13 1 site Stand-aloneOther conditions: Overweight Subject, Healthy SubjectsView official trial listing → -
Recruiting NCT NCT07335900
A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis
Not yet reported RenJi Hospital 25 participants Est. completion 2027-05-30 1 site Stand-aloneOther conditions: Severe Aortic Valve StenosisView official trial listing → -
Recruiting NCT NCT07336797
Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy
Not yet reported Abdelrahman Mahmoud 66 participants Est. completion 2027-12-30 1 site Stand-aloneMetabolic syndrome Other conditions: Obesity & Overweight, HIV (Human Immunodeficiency Virus)View official trial listing → -
Recruiting NCT NCT07372040
Add-on Diuretics in Acute Decompensated Heart Failure
Not yet reported Tanta University 66 participants Est. completion 2027-02-01 1 siteHeart failureView official trial listing → -
Recruiting NCT NCT07442006
Glycemic Variability of Combination Therapies in T2DM
Not yet reported JW Pharmaceutical 178 participants Est. completion 2027-03-31 1 site Stand-aloneType 2 diabetesView official trial listing → -
Recruiting NCT NCT07469943
The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness and Cardiac Deformation After Acute Myocardial Infarction
University of Athens 80 participants Est. completion 2028-12-20 1 siteCardiovascular disease Other conditions: Diabete Type 2View official trial listing → -
Recruiting NCT NCT07482020
SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism
Not yet reported Huashan Hospital 66 participants Est. completion 2027-06-30 1 siteOther conditions: Atrial Fibrillation (AF), HypertensionView official trial listing → -
Recruiting NCT NCT07513883
The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.
Not yet reported Ziekenhuis Oost-Limburg 100 participants Est. completion 2028-12 1 siteHeart failureView official trial listing → -
Recruiting NCT NCT07572032
Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study
Not yet reported Kyungsub Song 80 participants Est. completion 2028-12-20 4 sites Stand-aloneCardiovascular diseaseHeart failure Other conditions: Valvular CardiomyopathyView official trial listing → -
Recruiting NCT NCT07631156
STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure
Not yet reported Kyungsub Song 80 participants Est. completion 2029-12-30 5 sites Stand-aloneHeart failure Other conditions: Ventricular Dysfunction, LeftView official trial listing → -
Recruiting NCT NCT07692256
the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients
Not yet reported Ain Shams University 60 participants Est. completion 2027-02-01 1 site Stand-aloneHeart failureView official trial listing → -
Recruiting NCT NCT07771010
The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvascular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes Mellitus
Not yet reported University Medical Centre Ljubljana 54 participants Est. completion 2028-07-31 1 siteOther conditions: Diabetes Type 2View official trial listing → -
Recruiting NCT NCT07776054
Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF
Not yet reported Samsung Medical Center 200 participants Est. completion 2027-09-01 1 site Stand-aloneOther conditions: Atrial Fibrillation, SGLT2 Inhibitor, DC CardioversionView official trial listing → -
Completed NCT NCT00558571
4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes
Not yet reported Boehringer Ingelheim 78 participants 3 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT00749190
BI 10773 add-on to Metformin in Patients With Type 2 Diabetes
Not yet reported Boehringer Ingelheim 495 participants 116 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT00789035
12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
Not yet reported Boehringer Ingelheim 408 participants 74 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT00881530
Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
Not yet reported Boehringer Ingelheim 660 participants 137 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT00885118
4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
Not yet reported Boehringer Ingelheim 100 participants 5 sitesType 2 diabetesView official trial listing → -
Status unknown NCT NCT01001962
Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics
Not yet reported Aristotle University Of Thessaloniki 1054 participants Est. completion 2020-01 1 siteOther conditions: Hypertension, Type II DiabetesView official trial listing → -
Completed NCT NCT01011868
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
Not yet reported Boehringer Ingelheim 494 participants 99 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT01111318
Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function
Not yet reported Boehringer Ingelheim 36 participants 1 siteOther conditions: Hepatic Insufficiency, HealthyView official trial listing → -
Completed NCT NCT01111331
Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers
Not yet reported Boehringer Ingelheim 18 participants 1 siteOther conditions: HealthyView official trial listing → -
Completed NCT NCT01131676
BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
Not yet reported Boehringer Ingelheim 7064 participants Est. completion 2015-04 615 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT01164501
Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment
Not yet reported Boehringer Ingelheim 741 participants Est. completion 2012-07 127 sitesType 2 diabetes Other conditions: Renal InsufficiencyView official trial listing → -
Completed NCT NCT01167881
Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes
Not yet reported Boehringer Ingelheim 1549 participants Est. completion 2015-08 182 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT01177813
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Not yet reported Boehringer Ingelheim 986 participants 124 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT01189201
Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food
Not yet reported Boehringer Ingelheim 42 participants 1 siteOther conditions: HealthyView official trial listing → -
Completed NCT NCT01195675
Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects
Not yet reported Boehringer Ingelheim 30 participants 1 siteOther conditions: HealthyView official trial listing → -
Completed NCT NCT01210001
Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
Not yet reported Boehringer Ingelheim 499 participants 68 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT01211197
Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability
Not yet reported Boehringer Ingelheim 16 participants 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT01242176
Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers
Not yet reported Boehringer Ingelheim 24 participants 1 siteOther conditions: HealthyView official trial listing → -
Completed NCT NCT01248364
A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects
Not yet reported Boehringer Ingelheim 91 participants Est. completion 2013-07 3 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT01276288
Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 Diabetes
Not yet reported Boehringer Ingelheim 23 participants 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT01276301
DDI Between BI Empagliflozin (10773) and Verapamil
Not yet reported Boehringer Ingelheim 16 participants 1 siteOther conditions: HealthyView official trial listing → -
Completed NCT NCT01284621
Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers
Not yet reported Boehringer Ingelheim 23 participants 1 siteOther conditions: HealthyView official trial listing → -
Completed NCT NCT01289990
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
Not yet reported Boehringer Ingelheim 2705 participants Est. completion 2013-05 243 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT01301742
Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers
Not yet reported Boehringer Ingelheim 18 participants 1 siteOther conditions: HealthyView official trial listing → -
Completed NCT NCT01306175
Drug Interaction Study of Digoxin and BI 10773
Not yet reported Boehringer Ingelheim 20 participants 1 siteOther conditions: HealthyView official trial listing → -
Completed NCT NCT01306214
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
Not yet reported Boehringer Ingelheim 566 participants Est. completion 2013-04 103 sitesType 2 diabetes Other conditions: ObesityView official trial listing → -
Completed NCT NCT01316341
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Empagliflozin in Chinese Female and Male Patients With Type 2 Diabetes Mellitus
Not yet reported Boehringer Ingelheim 24 participants 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT01328184
Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon
Not yet reported Boehringer Ingelheim 18 participants 1 siteOther conditions: HealthyView official trial listing → -
Completed NCT NCT01368081
Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
Not yet reported Boehringer Ingelheim 1162 participants Est. completion 2013-04 87 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT01370005
12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
Not yet reported Boehringer Ingelheim 825 participants Est. completion 2012-07 120 sitesType 2 diabetes Other conditions: HypertensionView official trial listing → -
Completed NCT NCT01392560
Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration
Not yet reported Boehringer Ingelheim 52 participants Est. completion 2012-08 1 siteOther conditions: Diabetes Mellitus, Type 1View official trial listing → -
Completed NCT NCT01422876
Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Not yet reported Boehringer Ingelheim 1405 participants Est. completion 2013-09 211 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT01451775
Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.
Not yet reported Boehringer Ingelheim 18 participants 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT01581658
Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes
Not yet reported Boehringer Ingelheim 32 participants Est. completion 2012-11-01 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT01634100
Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid
Not yet reported Boehringer Ingelheim 18 participants Est. completion 2012-08 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT01649297
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
Not yet reported Boehringer Ingelheim 983 participants Est. completion 2013-12 139 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01719003
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
Not yet reported Boehringer Ingelheim 1413 participants Est. completion 2014-12 190 sites Stand-aloneType 2 diabetes Other conditions: HyperglycemiaView official trial listing → -
Completed NCT NCT01734785
Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes
Not yet reported Boehringer Ingelheim 607 participants Est. completion 2015-03-23 90 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01778049
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
Not yet reported Boehringer Ingelheim 708 participants Est. completion 2015-03 114 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01811953
Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together
Not yet reported Boehringer Ingelheim 48 participants Est. completion 2013-05 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT01844531
Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets
Not yet reported Boehringer Ingelheim 24 participants Est. completion 2013-11 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT01867307
Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
Not yet reported Boehringer Ingelheim 39 participants Est. completion 2015-10 1 site Stand-aloneType 2 diabetes Other conditions: HealthyView official trial listing → -
Completed NCT NCT01924767
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets
Not yet reported Boehringer Ingelheim 48 participants Est. completion 2007-11 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT01947855
Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
Not yet reported Boehringer Ingelheim 60 participants Est. completion 2013-12 2 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT01969747
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Not yet reported Boehringer Ingelheim 75 participants Est. completion 2014-04 2 sites Stand-aloneOther conditions: Diabetes Mellitus, Type 1View official trial listing → -
Withdrawn NCT NCT01984606
Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
Not yet reported Boehringer Ingelheim Est. completion 2017-02 Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02028767
Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets
Not yet reported Boehringer Ingelheim 32 participants Est. completion 2014-02 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT02041234
Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment
Not yet reported Khoo Teck Puat Hospital 40 participants Est. completion 2022-06 1 siteOther conditions: Type II Diabetes in Subjects BMI 27 to 32View official trial listing → -
Completed NCT NCT02102932
Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers
Not yet reported Boehringer Ingelheim 96 participants Est. completion 2014-08 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT02106923
Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets
Not yet reported Boehringer Ingelheim 72 participants Est. completion 2014-07 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT02121483
Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
Not yet reported Boehringer Ingelheim 27 participants Est. completion 2016-02 11 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02172209
Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male Volunteers
Not yet reported Boehringer Ingelheim 14 participantsOther conditions: HealthyView official trial listing → -
Completed NCT NCT02172235
Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers
Not yet reported Boehringer Ingelheim 20 participantsOther conditions: HealthyView official trial listing → -
Completed NCT NCT02172274
BI 10773 Administered as Oral Solution to Healthy Male Volunteers
Not yet reported Boehringer Ingelheim 8 participantsOther conditions: HealthyView official trial listing → -
Completed NCT NCT02230995
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects
Not yet reported Boehringer Ingelheim 30 participants Est. completion 2014-10 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT02266472
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female
Not yet reported Boehringer Ingelheim 30 participants Est. completion 2014-12 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Status unknown NCT NCT02284269
Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
Pharmaceuticals and Medical Devices Agency, Japan 18000 participantsType 2 diabetesView official trial listing → -
Completed NCT NCT02367131
Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus
Boehringer Ingelheim 419 participants Est. completion 2016-09-27 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT02401880
Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology
Not yet reported Profil Institut für Stoffwechselforschung GmbH 89 participants Est. completion 2015-12 2 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT02414958
Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
Not yet reported Boehringer Ingelheim 730 participants Est. completion 2017-10-23 131 sites Stand-aloneOther conditions: Diabetes Mellitus, Type 1View official trial listing → -
Completed NCT NCT02453555
Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
Not yet reported Boehringer Ingelheim 275 participants Est. completion 2017-03-27 40 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02489942
Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus
Boehringer Ingelheim 8145 participants Est. completion 2020-12-04 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT02489968
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus
Not yet reported Boehringer Ingelheim 880 participants Est. completion 2017-06-16 83 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02577315
Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
Not yet reported Boehringer Ingelheim 25 participants Est. completion 2015-10 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT02580591
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
Not yet reported Boehringer Ingelheim 977 participants Est. completion 2017-09-20 189 sites Stand-aloneOther conditions: Diabetes Mellitus, Type 1View official trial listing → -
Completed NCT NCT02589626
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
Not yet reported Boehringer Ingelheim 65 participants Est. completion 2017-06-02 16 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02597049
A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
Not yet reported Eli Lilly and Company 424 participants Est. completion 2017-02 41 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT02632747
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
Not yet reported Boehringer Ingelheim 31 participants Est. completion 2019-07-02 1 site Stand-aloneType 2 diabetes Other conditions: Diabetes Mellitus, Type 1, ObesityView official trial listing → -
Completed NCT NCT02636192
Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents
Janssen Research & Development, LLC 200000 participants Est. completion 2017-04-07Type 2 diabetesView official trial listing → -
Completed NCT NCT02637973
Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
Not yet reported The Deutsche Diabetes Forschungsgesellschaft e.V. 84 participants Est. completion 2018-08 5 sites Stand-aloneType 2 diabetes Other conditions: Non-alcoholic Fatty Liver DiseaseView official trial listing → -
Completed NCT NCT02686476
Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
Not yet reported Medanta, The Medicity, India 100 participants Est. completion 2017-12 1 siteOther conditions: Non Alcoholic Fatty Liver DiseaseView official trial listing → -
Completed NCT NCT02702011
Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus
Not yet reported Boehringer Ingelheim 48 participants Est. completion 2016-10-03 4 sites Stand-aloneOther conditions: Diabetes Mellitus, Type 1View official trial listing → -
Completed NCT NCT02729766
Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
Not yet reported, Not yet reported University Hospital, Basel, Switzerland 15 participants Est. completion 2016-08 1 siteOther conditions: Inappropriate ADH SyndromeView official trial listing → -
Completed NCT NCT02758171
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects
Not yet reported Boehringer Ingelheim 56 participants Est. completion 2016-08-03 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Withdrawn NCT NCT02768220
The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products
Not yet reported Northwell Health Est. completion 2018-12 Stand-aloneOther conditions: SGLT-2 Inhibitors, Advanced Glycation End Products, DiabetesView official trial listing → -
Completed NCT NCT02782624
Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers
Not yet reported Boehringer Ingelheim 16 participants Est. completion 2009-11 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT02792400
The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors
Not yet reported University Hospital, Gentofte, Copenhagen 24 participants Est. completion 2018-07 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT02798744
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.
Not yet reported University of Leicester 68 participants Est. completion 2019-07-30 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02815644
Empa/Lina FDC Food Effect Study (Japan)
Not yet reported Boehringer Ingelheim 22 participants Est. completion 2016-10-05 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT02821910
Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets
Not yet reported Boehringer Ingelheim 50 participants Est. completion 2016-10-31 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT02833415
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
Not yet reported University of Texas Southwestern Medical Center 40 participants Est. completion 2018-11 1 site Stand-aloneOther conditions: Obesity, VisceralView official trial listing → -
Status unknown NCT NCT02854748
Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin
Not yet reported Chong Kun Dang Pharmaceutical 30 participants Est. completion 2016-09 1 site Stand-aloneOther conditions: Diabetes Mellitus, Type IIView official trial listing → -
Completed NCT NCT02857764
Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States
Janssen Research & Development, LLC 127690 participants Est. completion 2017-06-30Type 2 diabetesView official trial listing → -
Completed NCT NCT02863328
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
Not yet reported Novo Nordisk A/S 822 participants Est. completion 2018-03-08 106 sitesType 2 diabetes Other conditions: DiabetesView official trial listing → -
Completed NCT NCT02890745
The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes
Not yet reported Henrik Enghusen Poulsen 31 participants Est. completion 2020-01-22 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT02932436
Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics
Not yet reported Johannes Gutenberg University Mainz 144 participants Est. completion 2020-08-31 1 site Stand-aloneType 2 diabetes Other conditions: Diastolic DysfunctionView official trial listing → -
Completed NCT NCT02964572
Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
Not yet reported Yonsei University 61 participants Est. completion 2017-07 1 site Stand-aloneType 2 diabetesView official trial listing → -
Status unknown NCT NCT02964715
The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes
Not yet reported University of Malaya 25 participants Est. completion 2018-11 1 site Stand-aloneType 2 diabetesMASLDView official trial listing → -
Terminated NCT NCT02985242
Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema
Not yet reported Hannover Medical School 6 participants Est. completion 2018-08-16 1 site Stand-aloneOther conditions: Diabetes Mellitus, Type IIView official trial listing → -
Status unknown NCT NCT02998970
Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes
Not yet reported Unity Health Toronto 97 participants Est. completion 2018-09 1 siteCardiovascular disease Other conditions: DiabetesView official trial listing → -
Completed NCT NCT03008551
Empagliflozin vs Metformin in PCOS
Not yet reported, Not yet reported Hull University Teaching Hospitals NHS Trust 40 participants Est. completion 2018-04-02 1 site Stand-aloneOther conditions: Polycystic Ovary SyndromeView official trial listing → -
Completed NCT NCT03027960
Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects
Not yet reported Yale University 21 participants Est. completion 2019-06-01 1 site Stand-aloneHeart failure Other conditions: Type II; DiabetesView official trial listing → -
Completed NCT NCT03030222
Empagliflozin Impact on Hemodynamics in Patients With Heart Failure
Not yet reported Saint Luke's Health System 65 participants Est. completion 2020-03-10 10 sitesHeart failureView official trial listing → -
Completed NCT NCT03050619
Characteristics of Empagliflozin Initiators
Boehringer Ingelheim 31908 participants Est. completion 2016-10-14 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT03057951
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
Not yet reported Boehringer Ingelheim 5988 participants Est. completion 2021-04-26 619 sites Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT03057977
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)
Not yet reported Boehringer Ingelheim 3730 participants Est. completion 2020-05-28 520 sites Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT03059056
Pharmacokinetic Evaluation of Empagliflozin
Not yet reported British University In Egypt 6 participants Est. completion 2017-02-02 Stand-aloneOther conditions: Diabetes MellitusView official trial listing → -
Terminated NCT NCT03060980
Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin
Not yet reported Intarcia Therapeutics 245 participants Est. completion 2018-01-26 101 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03087773
Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction
Not yet reported Medical University of Graz 476 participants Est. completion 2022-05-17 11 sitesCardiovascular diseaseView official trial listing → -
Completed NCT NCT03093103
Empagliflozin and Renal Oxygenation in Healthy Volunteers
Not yet reported Centre Hospitalier Universitaire Vaudois 45 participants Est. completion 2018-12-31 1 siteOther conditions: NephropathyView official trial listing → -
Completed NCT NCT03113110
Empagliflozin in Post-Transplantation Diabetes Mellitus
Not yet reported Medical University of Vienna 16 participants Est. completion 2018-05-31 1 siteOther conditions: Posttransplant Diabetes MellitusView official trial listing → -
Completed NCT NCT03118336
Impact of Empaglifozine on Cardiac Ectopic Fat
Not yet reported Assistance Publique Hopitaux De Marseille 56 participants Est. completion 2020-02-07 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03128528
Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure
Not yet reported University of Erlangen-Nürnberg Medical School 84 participants Est. completion 2020-04-30 1 siteHeart failureView official trial listing → -
Completed NCT NCT03132181
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes
Not yet reported RWTH Aachen University 40 participants Est. completion 2019-01-23 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03157414
Empagliflozin in Renal Transplant Recipients
Not yet reported Oslo University Hospital 49 participants Est. completion 2018-06-28 1 siteOther conditions: Diabetes Mellitus, Renal Insufficiency, Safety IssuesView official trial listing → -
Withdrawn NCT NCT03173963
Empaglifozin in Early Diabetic Kidney Disease
Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Est. completion 2020-02-21 1 siteChronic kidney diseaseType 2 diabetesView official trial listing → -
Completed NCT NCT03193684
Empagliflozin and Hepatic Glucose Metabolism
Not yet reported The University of Texas Health Science Center at San Antonio 72 participants Est. completion 2024-01-30 1 site Stand-aloneOther conditions: Hepatic Glucose MetabolismView official trial listing → -
Completed NCT NCT03198585
Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction
Not yet reported Morten Schou 190 participants Est. completion 2020-01-17 2 sitesHeart failureView official trial listing → -
Completed NCT NCT03200782
Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study
Not yet reported University Hospital, Basel, Switzerland 12 participants Est. completion 2018-09-21 1 siteOther conditions: Postprandial Hypoglycemia, Bariatric Surgery, Late Dumping SyndromeView official trial listing → -
Completed NCT NCT03200860
Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure
Not yet reported University Medical Center Groningen 80 participants Est. completion 2019-09-18 5 sitesHeart failureView official trial listing → -
Completed NCT NCT03202667
Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study
Not yet reported, Not yet reported University Hospital, Basel, Switzerland 17 participants Est. completion 2021-12-06 1 siteOther conditions: SIAD - Syndrome of Inappropriate Antidiuresis, HyponatremiaView official trial listing → -
Completed NCT NCT03215069
Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational Diabetes
Not yet reported Mount Sinai Hospital, Canada 91 participants Est. completion 2024-12-31 1 site Stand-aloneOther conditions: Gestational DiabetesView official trial listing → -
Completed NCT NCT03226457
SGLT2 Inhibition in Combination With Diuretics in Heart Failure
Not yet reported University of Dundee 23 participants Est. completion 2019-01-09 1 siteHeart failureType 2 diabetesView official trial listing → -
Completed NCT NCT03227484
Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes
Not yet reported University Hospital Tuebingen 42 participants Est. completion 2019-11-18 1 sitePrediabetes Other conditions: Body WeightView official trial listing → -
Completed NCT NCT03249506
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
Janssen Research & Development, LLC 25358 participants Est. completion 2017-11-01 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT03254849
Empagliflozin and Sympathetic Nerve Traffic
Not yet reported Profil Institut für Stoffwechselforschung GmbH 75 participants Est. completion 2020-04-20 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03259490
This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood
Not yet reported Boehringer Ingelheim 30 participants Est. completion 2017-11-13 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Status unknown NCT NCT03271879
Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
Not yet reported Rambam Health Care Campus 128 participants Est. completion 2020-06-01Heart failure Other conditions: Diabetes Mellitus, ArrythmiaView official trial listing → -
Completed NCT NCT03332212
A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin
Not yet reported Boehringer Ingelheim 72 participants Est. completion 2020-05-28 1 site Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT03363464
Comparative Effectiveness of Empagliflozin in the US
Boehringer Ingelheim 230000 participants Est. completion 2026-07-09 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT03422263
Performance Under SGLT-2-Inhibitors in Humans
Berner Klinik Montana 450 participants Est. completion 2020-09-30 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT03429543
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
Not yet reported Boehringer Ingelheim 175 participants Est. completion 2023-05-31 83 sites Stand-aloneType 2 diabetesView official trial listing → -
Status unknown NCT NCT03433248
Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES
Not yet reported M.H.H. Kramer 66 participants Est. completion 2022-09-01 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03448406
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
Not yet reported Boehringer Ingelheim 315 participants Est. completion 2019-10-09 108 sites Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT03448419
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
Not yet reported Boehringer Ingelheim 312 participants Est. completion 2019-10-07 109 sites Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT03462069
Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension
Not yet reported Sanofi 41 participants Est. completion 2019-04-18 1 site Stand-aloneOther conditions: Diabetes MellitusView official trial listing → -
Completed NCT NCT03464045
Empa PASS on Urinary Tract Malignancies
Boehringer Ingelheim 344995 participants Est. completion 2024-03-11 3 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT03473262
Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes
Chungbuk National University Hospital 200 participants Est. completion 2018-07-18Type 2 diabetesView official trial listing → -
Completed NCT NCT03485092
Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects
Not yet reported NHS Greater Glasgow and Clyde 105 participants Est. completion 2020-03-28 1 siteHeart failure Other conditions: Diabetes MellitusView official trial listing → -
Completed NCT NCT03492580
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Janssen Research & Development, LLC 714582 participants Est. completion 2018-06-25 1 siteType 2 diabetesCardiovascular diseaseView official trial listing → -
Completed NCT NCT03560375
Mediterranean Diet, Circuit Resistance Training, Empagliflozin in Elderly With Type 2 Diabetes: a Study Protocol
Not yet reported Tel-Aviv Sourasky Medical Center 100 participants Est. completion 2021-02-10 1 site Stand-aloneType 2 diabetes Other conditions: Sarcopenia, Weight LossView official trial listing → -
Status unknown NCT NCT03565458
Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
Not yet reported LG Chem 48 participants Est. completion 2018-12-22 1 site Stand-aloneType 2 diabetesView official trial listing → -
Status unknown NCT NCT03591991
Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI
Not yet reported Chinese PLA General Hospital 128 participants Est. completion 2019-09-01Other conditions: Reperfusion Injury, MyocardialView official trial listing → -
Status unknown NCT NCT03627039
Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)
Brigham and Women's Hospital 20000 participants Est. completion 2020-08-01 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT03629054
This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
Not yet reported Boehringer Ingelheim 30 participants Est. completion 2018-11-05 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Status unknown NCT NCT03639545
The Effects of Empagliflozin on Arterial Wall Characteristics
Not yet reported University Medical Centre Ljubljana 120 participants Est. completion 2019-01-30 1 siteOther conditions: Vascular Stiffness, Hypoglycemic Agents, Diabetes Complications, Diabetes Mellitus, Type 1View official trial listing → -
Terminated NCT NCT03642184
Efficacy and Safety of Empagliflozin in NODAT
Not yet reported RenJi Hospital 6 participants Est. completion 2019-01-31 1 siteOther conditions: New Onset Diabetes After Transplant, Kidney Transplant; ComplicationsView official trial listing → -
Completed NCT NCT03642717
Regulatory Request NIS in Korea
Boehringer Ingelheim 658 participants Est. completion 2020-04-30 20 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT03646292
Antidiabetic Drugs for Steatotic Liver Disease
Not yet reported Yonsei University 51 participants Est. completion 2022-06-16 1 site Stand-aloneMASLDType 2 diabetes Other conditions: Digestive System Disease, Liver Diseases, Fatty Liver, Non-Alcoholic Fatty Liver Disease, Hypoglycemic Agents, Physiological Effects of Drugs, Sodium-Glucose Cotransporter 2 Inhibitors, Pioglitazone, Molecular Mechanisms of Pharmacological Action, Empagliflozin, ThiazolidinedionesView official trial listing → -
Completed NCT NCT03748810
Head-to-head Comparison of Empagliflozin and Dapagliflozin
Chungbuk National University Hospital 600 participants Est. completion 2022-06-30 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT03753087
Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus
Not yet reported National Medical Research Center for Cardiology, Ministry of Health of Russian Federation 70 participants Est. completion 2022-01-10 1 site Stand-aloneHeart failureType 2 diabetesView official trial listing → -
Completed NCT NCT03764631
Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration
Boehringer Ingelheim 1502 participants Est. completion 2021-01-11 21 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT03771781
Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.
Not yet reported Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 48 participants Est. completion 2018-05-25 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT03790787
Drug Interaction Study Between Dorzagliatin and Empagliflozin
Not yet reported Hua Medicine Limited 16 participants Est. completion 2020-03-15 1 site Stand-aloneOther conditions: PatientsView official trial listing → -
Status unknown NCT NCT03804411
Prognostic Predictors of Response to Hypoglycemic Therapy
Not yet reported Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health 800 participants Est. completion 2020-05 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT03807440
DIA_CENTRAL:T2D Treatment Pattern in Central Europe
Boehringer Ingelheim 4083 participants Est. completion 2021-08-31 177 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT03852901
Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production
Not yet reported National Institute on Aging (NIA) 21 participants Est. completion 2021-12-13 1 site Stand-aloneOther conditions: Empaglifozin, Physiological Effects of Drugs, Hypoglycemic Agents, Sodium-Glucose Transporter 2 InhibitorsView official trial listing → -
Not yet recruiting NCT NCT03867487
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
Not yet reported Justin Ryder 40 participants Est. completion 2028-02-01 1 site Stand-aloneMASLD Other conditions: Non-Alcoholic Fatty Liver DiseaseView official trial listing → -
Completed NCT NCT03895229
The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin
Not yet reported Ain Shams University 16 participants Est. completion 2018-10-26 1 site Stand-aloneOther conditions: Diabetes Mellitus, Pharmacokinetics, PharmacodynamicsView official trial listing → -
Status unknown NCT NCT03912909
Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans
Not yet reported Royal Perth Hospital 30 participants Est. completion 2024-12-30 1 siteMetabolic syndromeType 2 diabetes Other conditions: ObesityView official trial listing → -
Status unknown NCT NCT03917758
Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors
Not yet reported University of Turin, Italy 30 participants Est. completion 2020-10-30 1 siteType 2 diabetes Other conditions: Arterial Hypertension, Body Weight ChangesView official trial listing → -
Completed NCT NCT03918148
Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)
University of Campania Luigi Vanvitelli 1150 participants Est. completion 2023-12-31 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT03979352
Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting
Not yet reported Samuel Lunenfeld Research Institute, Mount Sinai Hospital 28 participants Est. completion 2021-08-31 2 sitesOther conditions: Type1 Diabetes MellitusView official trial listing → -
Completed NCT NCT04013581
Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen
Not yet reported Yonsei University 121 participants Est. completion 2020-05-28 1 siteType 2 diabetesView official trial listing → -
Status unknown NCT NCT04014192
Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus
Not yet reported Peking Union Medical College Hospital 40 participants Est. completion 2020-07-31 1 site Stand-aloneType 2 diabetesView official trial listing → -
Status unknown NCT NCT04027023
Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus
Not yet reported Sciema UG 9 participants Est. completion 2021-05-31 2 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT04043702
Combination of Topiramate and Empagliflozin is Considered a Good Option for the Treatment of Obesity
Ministry of Health and Population, Egypt 200 participants Est. completion 2019-07-29 1 siteOther conditions: ObesityView official trial listing → -
Completed NCT NCT04049045
Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure
Not yet reported Christian Schulze 60 participants Est. completion 2021-06-29 1 siteHeart failureView official trial listing → -
Status unknown NCT NCT04061200
Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria
Not yet reported Steno Diabetes Center Copenhagen 80 participants Est. completion 2021-08-01 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT04061473
Involvement of Dipeptidyl Peptidase-4 and Sodium-glucose Co-transporter-2 in Extrapancreatic Glucagon Secretion
Not yet reported University Hospital, Gentofte, Copenhagen 20 participants Est. completion 2019-08-20 1 siteOther conditions: Diabetes After Total PancreatectomyView official trial listing → -
Completed NCT NCT04117763
Effect of Empagliflozin on Ventricular Repolarization.
Not yet reported University of Sao Paulo 90 participants Est. completion 2024-03-31 1 site Stand-aloneType 2 diabetes Other conditions: Coronary Heart Disease, Arrythmia, CardiacView official trial listing → -
Status unknown NCT NCT04127084
Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes
Not yet reported Zhongshan Hospital Xiamen University 70 participants Est. completion 2021-08 1 siteType 2 diabetesChronic kidney diseaseView official trial listing → -
Status unknown NCT NCT04131582
Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes
Not yet reported Universidad de Guanajuato 34 participants Est. completion 2020-12-30 1 site Stand-aloneOther conditions: Prediabetic State, Insulin ResistanceView official trial listing → -
Status unknown NCT NCT04138251
Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency
Not yet reported Cliniques universitaires Saint-Luc- Université Catholique de Louvain 5 participants Est. completion 2020-06-30 1 site Stand-aloneOther conditions: Glycogen Storage Disease Type I, Glucose 6 Phosphatase DeficiencyView official trial listing → -
Completed NCT NCT04143321
Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina
Not yet reported Isfahan University of Medical Sciences 75 participants Est. completion 2019-05-23 1 site Stand-aloneOther conditions: Diabetes MellitusView official trial listing → -
Completed NCT NCT04183868
Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)
Not yet reported University of Catanzaro 26 participants Est. completion 2021-10 1 site Stand-aloneType 2 diabetes Other conditions: Cardiovascular Risk FactorView official trial listing → -
Completed NCT NCT04184947
Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists
University of Padova 10000 participants Est. completion 2020-02-29 1 siteType 2 diabetesView official trial listing → -
Status unknown NCT NCT04195243
Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus
Not yet reported Centro Universitario de Ciencias de la Salud, Mexico 24 participants Est. completion 2020-12-30 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT04196231
Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)
Not yet reported University of Campania Luigi Vanvitelli 258 participants Est. completion 2020-10-20 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT04201496
SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus
Not yet reported Ananda Basu, MD 34 participants Est. completion 2021-09-07 1 site Stand-aloneOther conditions: Type 1 DiabetesView official trial listing → -
Completed NCT NCT04203914
Short Term Effect of Empagliflozin in Hypertension
Not yet reported Yaounde Central Hospital 15 participants Est. completion 2017-09-30 2 sites Stand-aloneOther conditions: HypertensionView official trial listing → -
Status unknown NCT NCT04203927
Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes
Not yet reported University of Virginia 50 participants Est. completion 2023-11-30 1 siteType 2 diabetes Other conditions: Insulin SensitivityView official trial listing → -
Status unknown NCT NCT04215445
Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD
Not yet reported National University of Malaysia 90 participants Est. completion 2020-08 1 siteChronic kidney disease Other conditions: Diabetic Retinopathy, Diabetes MellitusView official trial listing → -
Completed NCT NCT04215536
Replication of the EMPAREG Diabetes Trial in Healthcare Claims
Brigham and Women's Hospital 103752 participants Est. completion 2021-02-18 1 siteOther conditions: DiabetesView official trial listing → -
Status unknown NCT NCT04221152
A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )
Not yet reported Kobe University 8 participants Est. completion 2022-05-31 5 sites Stand-aloneOther conditions: Insulin Resistance - Type A, Insulin Resistance - Type B, Lipoatrophic Diabetes Mellitus, Insulin Resistance SyndromeView official trial listing → -
Completed NCT NCT04233801
A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
Not yet reported Boehringer Ingelheim 219 participants Est. completion 2022-03-10 24 sites Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT04238702
Renohemodynamic Effects of Combined empagliflOzin and LosARtan
Not yet reported Amsterdam UMC, location VUmc 24 participants Est. completion 2021-09-27 1 site Stand-aloneType 2 diabetesChronic kidney diseaseView official trial listing → -
Withdrawn NCT NCT04243850
REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs Populations
Not yet reported Amsterdam UMC, location VUmc Est. completion 2022-03-01 Stand-aloneType 2 diabetesChronic kidney diseaseView official trial listing → -
Completed NCT NCT04295005
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
Boehringer Ingelheim 24500 participants Est. completion 2021-09-30 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT04342819
The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.
Not yet reported, Not yet reported The University of The West Indies 25 participants Est. completion 2021-12-31 1 site Stand-aloneOther conditions: Platelet Dysfunction Due to DrugsView official trial listing → -
Completed NCT NCT04345796
Pharmacological Reduction of Right Ventricular Enlargement
Not yet reported Asan Medical Center 56 participants Est. completion 2024-06-03 3 sitesOther conditions: Tricuspid Regurgitation, Right Ventricular DilatationView official trial listing → -
Status unknown NCT NCT04419337
Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke
Not yet reported Chang Gung Memorial Hospital 200 participants Est. completion 2024-01-31 1 site Stand-aloneCardiovascular disease Other conditions: Diabetes MellitusView official trial listing → -
Completed NCT NCT04431141
Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin
Not yet reported Handok Inc. 32 participants Est. completion 2021-01-25 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT04450563
Low Dose Empagliflozin in Adults With Type 1 Diabetes on Closed Loop Insulin System
Not yet reported McGill University 25 participants Est. completion 2022-01-13 1 site Stand-aloneOther conditions: Type 1 DiabetesView official trial listing → -
Completed NCT NCT04461041
Empagliflozin and Cardiac Remodelling in People Without Diabetes
Not yet reported Unity Health Toronto 169 participants Est. completion 2022-07-31 4 sitesCardiovascular disease Other conditions: Left Ventricular HypertrophyView official trial listing → -
Completed NCT NCT04505774
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
Not yet reported Matthew Neal MD 3591 participants Est. completion 2024-01-26 101 sitesOther conditions: Covid19View official trial listing → -
Completed NCT NCT04509674
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
Not yet reported Boehringer Ingelheim 6522 participants Est. completion 2023-11-05 439 sites Stand-aloneCardiovascular diseaseView official trial listing → -
Status unknown NCT NCT04520646
A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
Not yet reported Huashan Hospital 10 participants Est. completion 2022-08-31 1 site Stand-aloneOther conditions: Acromegaly, CardiomyopathiesView official trial listing → -
Completed NCT NCT04523064
POST-CABGDM: Empagliflozin in Perioperative CABG
Not yet reported University of Sao Paulo General Hospital 155 participants Est. completion 2024-01-30 1 siteType 2 diabetesCardiovascular disease Other conditions: Coronary Artery Bypass Surgery, Acute Kidney InjuryView official trial listing → -
Completed NCT NCT04531462
A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years
Not yet reported Boehringer Ingelheim 129 participants Est. completion 2022-08-26 18 sites Stand-aloneType 2 diabetesView official trial listing → -
Status unknown NCT NCT04535960
Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial
Not yet reported University Health Network, Toronto 36 participants Est. completion 2023-10 1 site Added to GLP-1Type 2 diabetesView official trial listing → -
Active, not recruiting NCT NCT04541797
Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)
Not yet reported The University of Hong Kong 160 participants Est. completion 2025-02-28 1 site Stand-aloneType 2 diabetesCardiovascular diseaseView official trial listing → -
Status unknown NCT NCT04583813
Empagliflozin and Atrial Fibrillation Treatment
Not yet reported Miulli General Hospital 400 participants Est. completion 2024-04 1 siteHeart failure Other conditions: Atrial Fibrillation, Obesity, Diabetes MellitusView official trial listing → -
Status unknown NCT NCT04603508
Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia
Not yet reported EMS 240 participants Est. completion 2025-08 Stand-aloneType 2 diabetes Other conditions: DyslipidemiaView official trial listing → -
Completed NCT NCT04639414
Combined Active Treatment in Type 2 Diabetes With NASH
Not yet reported German Diabetes Center 192 participants Est. completion 2025-11-17 26 sites Added to GLP-1Type 2 diabetesMASHMASLDView official trial listing → -
Completed NCT NCT04642261
Effect of Empagliflozin on Liver Fat in Non-diabetic Patients
Not yet reported The University of Hong Kong 98 participants Est. completion 2023-06-30 1 site Stand-aloneOther conditions: Non-alcoholic Fatty Liver DiseaseView official trial listing → -
Status unknown NCT NCT04662866
Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose
Not yet reported Oslo University Hospital 64 participants Est. completion 2023-10 1 sitePrediabetes Other conditions: Insulin Sensitivity, Glucose Metabolism DisordersView official trial listing → -
Completed NCT NCT04665284
Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus
Not yet reported Getz Pharma 244 participants Est. completion 2020-09-28 11 sites Stand-aloneOther conditions: Type II Diabetes MellitusView official trial listing → -
Status unknown NCT NCT04702490
Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
Not yet reported Metacrine, Inc. 120 participants Est. completion 2022-06 2 sites Stand-aloneMASHType 2 diabetesMASLD Other conditions: Diabetes Type 2, Diabetes, Fatty Liver, Fatty Liver, NonalcoholicView official trial listing → -
Completed NCT NCT04735042
SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.
University of Pisa 60 participants Est. completion 2022-04-07 1 siteType 2 diabetes Other conditions: Urinary Tract InfectionsView official trial listing → -
Status unknown NCT NCT04853615
SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?
Fayoum University 800 participants Est. completion 2024-08-01Other conditions: SGLT2i Kideny Protection Against Contrast in Diabetic KidneyView official trial listing → -
Completed NCT NCT04869800
Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg
Not yet reported Chong Kun Dang Pharmaceutical 32 participants Est. completion 2021-06-15 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT04907214
SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot
Not yet reported, Not yet reported Vanderbilt University Medical Center 29 participants Est. completion 2023-12-08 1 site Stand-alonePrediabetes Other conditions: ObesityView official trial listing → -
Completed NCT NCT04910178
Follow-up of NAFLD Patients With MRI-PDFF
Not yet reported Asmaa Abdelfattah Elsayed 80 participants Est. completion 2021-12-30 1 site Stand-aloneMASLD Other conditions: Diabetes Type 2View official trial listing → -
Withdrawn NCT NCT04917692
Empagliflozin in Adolescent Diabetes
Not yet reported Ohio State University Est. completion 2022-10 1 site Stand-aloneOther conditions: type1diabetesView official trial listing → -
Completed NCT NCT04918407
Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation
Not yet reported Shahid Beheshti University of Medical Sciences 40 participants Est. completion 2025-08-05 2 sites Stand-aloneOther conditions: Kidney Transplant; ComplicationsView official trial listing → -
Completed NCT NCT04927858
A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017
Boehringer Ingelheim 460558 participants Est. completion 2018-11-15 1 siteType 2 diabetesView official trial listing → -
Status unknown NCT NCT04930627
Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia
Not yet reported Children's Memorial Health Institute, Poland 20 participants Est. completion 2025-03 1 site Stand-aloneOther conditions: Glucose 6 Phosphatase DeficiencyView official trial listing → -
Completed NCT NCT04937816
This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations
Boehringer Ingelheim 16746 participants Est. completion 2021-07-13 1 siteType 2 diabetesView official trial listing → -
Status unknown NCT NCT04961931
Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease
Not yet reported Medical University of Lodz 45 participants Est. completion 2021-08-31 1 siteChronic kidney diseaseView official trial listing → -
Withdrawn NCT NCT04970108
Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension
Not yet reported EMS Est. completion 2025-05 Stand-aloneOther conditions: Hypertension Associated, Type II Diabetes MellitusView official trial listing → -
Status unknown NCT NCT04976283
Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
Not yet reported Getz Pharma 123 participants Est. completion 2023-11-15 1 siteType 2 diabetesMASHMASLDView official trial listing → -
Status unknown NCT NCT04986735
Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin
Hong Kong Children's Hospital 11 participants Est. completion 2023-12-31 1 siteOther conditions: Glycogen Storage Disease Type IBView official trial listing → -
Completed NCT NCT05013112
Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)
Not yet reported West China Hospital 105 participants Est. completion 2025-12-31 1 site Stand-aloneOther conditions: Kidney Transplantation, Metabolic Disorder, Metformin, EmpagliflozinView official trial listing → -
Completed NCT NCT05013502
Empagliflozin in Diuretic Refractory Ascites
Not yet reported Stanford University 14 participants Est. completion 2023-06-30 1 site Stand-aloneOther conditions: Liver Cirrhosis, Cirrhosis, Ascites, Ascites Hepatic, Sodium-Glucose Transporter 2 InhibitorsView official trial listing → -
Enrolling by invitation NCT NCT05029115
The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus
Ewha Womans University Mokdong Hospital 716 participants Est. completion 2026-12 1 siteType 2 diabetes Other conditions: SGLT-2 Inhibitor, Atrial FibrillationView official trial listing → -
Status unknown NCT NCT05041673
Anti-diabetic Drugs and Fatty Liver Management
Not yet reported Alexandria University 120 participants Est. completion 2022-09-30 1 site Stand-aloneType 2 diabetes Other conditions: Fatty Liver, NonalcoholicView official trial listing → -
Completed NCT NCT05042973
The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure
Not yet reported Jacob Moller 165 participants Est. completion 2025-01-23 2 sitesHeart failure Other conditions: ObesityView official trial listing → -
Withdrawn NCT NCT05058417
Assessment of Empagliflozin as Adjuvant Therapy in Patients With Ulcerative Colitis
Not yet reported Sadat City University Est. completion 2025-12-31 1 site Stand-aloneOther conditions: Ulcerative ColitisView official trial listing → -
Completed NCT NCT05073692
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
Kaiser Permanente 241981 participants Est. completion 2025-03-12 6 sitesType 2 diabetesCardiovascular diseaseView official trial listing → -
Completed NCT NCT05078879
Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency
Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 4 participants Est. completion 2025-05-21 1 site Stand-aloneOther conditions: Crohn's Disease, Glycogen Metabolism, Inflammatory Bowel Disease (IBD)View official trial listing → -
Completed NCT NCT05081219
SNIFF - Combo INI+EMPA Trial
Not yet reported Wake Forest University Health Sciences 47 participants Est. completion 2024-09-17 1 site Stand-aloneOther conditions: Mild Cognitive Impairment, Cognitive Impairment, Alzheimer DiseaseView official trial listing → -
Completed NCT NCT05083949
A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together
Not yet reported Boehringer Ingelheim 32 participants Est. completion 2021-09-09 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT05084235
The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure
Not yet reported Jacob Moller 191 participants Est. completion 2025-01-16 2 sitesHeart failure Other conditions: ObesityView official trial listing → -
Status unknown NCT NCT05103306
Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy
Chungbuk National University Hospital 300 participants Est. completion 2022-12Type 2 diabetesView official trial listing → -
Status unknown NCT NCT05109949
Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes
Not yet reported Centro Universitario de Ciencias de la Salud, Mexico 72 participants Est. completion 2022-08-01 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT05130463
Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus
Boehringer Ingelheim 1053 participants Est. completion 2024-07-08 30 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT05132023
Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)
Not yet reported Genuine Research Center, Egypt 26 participants Est. completion 2019-05-15 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT05139472
Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction
Not yet reported University of Texas Southwestern Medical Center 8 participants Est. completion 2024-02-19 2 sites Stand-aloneHeart failure Other conditions: Diabetes MellitusView official trial listing → -
Status unknown NCT NCT05140694
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
Not yet reported Seoul National University Bundang Hospital 135 participants Est. completion 2025-12-31 MixedType 2 diabetes Other conditions: Metabolic-associated Fatty Liver DiseaseView official trial listing → -
Withdrawn NCT NCT05144360
Efficacy and Safety of Atenas Association in the Treatment of Type II Diabetes Mellitus and Hypertension
Not yet reported EMS Est. completion 2024-11 Stand-aloneOther conditions: Hypertension Associated, Type II Diabetes MellitusView official trial listing → -
Active, not recruiting NCT NCT05147090
Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients
Not yet reported The University of Hong Kong 106 participants Est. completion 2027-12-31 1 siteMASLD Other conditions: Chronic Hepatitis b, Cirrhosis, Fibrosis, Liver, Empagliflozin, SGLT2 InhibitorsView official trial listing → -
Completed NCT NCT05162014
To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin
Boehringer Ingelheim 494679 participants Est. completion 2022-09-12 1 siteType 2 diabetesView official trial listing → -
Withdrawn NCT NCT05174507
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes
Not yet reported University Hospital, Basel, Switzerland Est. completion 2026-05-01Other conditions: Postprandial HypoglycemiaView official trial listing → -
Active, not recruiting NCT NCT05182658
Empagliflozin in Hypertrophic Cardiomyopathy
Not yet reported National Institute of Cardiology, Warsaw, Poland 250 participants Est. completion 2026-11-30 2 sitesHeart failure Other conditions: Hypertrophic CardiomyopathyView official trial listing → -
Status unknown NCT NCT05200793
Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome
Not yet reported Alexandria University 75 participants Est. completion 2022-09-01 1 siteOther conditions: Polycystic Ovary Syndrome (PCOS)View official trial listing → -
Completed NCT NCT05232071
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
Not yet reported Inventiva Pharma 39 participants Est. completion 2024-06-04 42 sites Stand-aloneMASHType 2 diabetesView official trial listing → -
Completed NCT NCT05233163
SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy
Not yet reported Columbia University 15 participants Est. completion 2023-05-01 1 site Stand-aloneOther conditions: Transthyretin Amyloid CardiomyopathyView official trial listing → -
Completed NCT NCT05254002
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Not yet reported Bayer 1664 participants Est. completion 2025-03-17 173 sites Stand-aloneType 2 diabetesChronic kidney diseaseView official trial listing → -
Completed NCT NCT05262764
Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)
Boehringer Ingelheim 1200 participants Est. completion 2024-06-28 1 siteHeart failureView official trial listing → -
Active, not recruiting NCT NCT05271162
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines
Not yet reported Maria Sklodowska-Curie National Research Institute of Oncology 220 participants Est. completion 2028-02-24 2 sitesOther conditions: CardiotoxicityView official trial listing → -
Completed NCT NCT05278962
HF Patients With LVADs Being Treated With SGLT2i
Not yet reported University of Chicago 32 participants Est. completion 2025-08-31 1 siteHeart failureView official trial listing → -
Completed NCT NCT05283057
Empagliflozin in Patients With Glomerulonephritis
Not yet reported Kasr El Aini Hospital 50 participants Est. completion 2021-09-30 1 siteOther conditions: Glomerulonephritis, ProteinuriaView official trial listing → -
Completed NCT NCT05313529
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
Not yet reported The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 396 participants Est. completion 2026-07-01 5 sites Stand-aloneType 2 diabetes Other conditions: Mild Cognitive ImpairmentView official trial listing → -
Status unknown NCT NCT05333159
The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.
Beijing Anzhen Hospital 1424 participants Est. completion 2024-12-30 1 siteCardiovascular disease Other conditions: Diabete MellitusView official trial listing → -
Completed NCT NCT05344963
Deformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 Inhibitors
Matteo Cameli 503 participants Est. completion 2024-06-01 1 siteHeart failure Other conditions: Sodium-GLucose coTransporter-2 InhibitorsView official trial listing → -
Status unknown NCT NCT05347459
Cognitive Protective Effect of Newer Antidiabetic Drugs
Alexandria University 100 participants Est. completion 2023-12 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT05350202
Emp-Activity: Empagliflozin Functional Capacity
Boehringer Ingelheim 3431 participants Est. completion 2024-07-25 350 sitesHeart failureView official trial listing → -
Completed NCT NCT05359341
Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?
Not yet reported Sadat City University 175 participants Est. completion 2022-01-10 1 siteOther conditions: Diabete Type 2View official trial listing → -
Active, not recruiting NCT NCT05360615
The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors
Not yet reported Chulalongkorn University 147 participants Est. completion 2026-07-01 1 site Stand-aloneOther conditions: Empagliflozin in Post AKI Stage 2-3View official trial listing → -
Completed NCT NCT05364190
Canagliflozin in Patients With Acute Decompansted Heart Failure
Not yet reported October 6 University 142 participants Est. completion 2024-03-01 1 siteHeart failure Other conditions: Diabetes MellitusView official trial listing → -
Status unknown NCT NCT05373004
Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease
Not yet reported, Not yet reported Omar Tarek Elfarargi 212 participants Est. completion 2024-05 Stand-aloneChronic kidney diseaseView official trial listing → -
Completed NCT NCT05373680
Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression
Not yet reported, Not yet reported Tanta University 118 participants Est. completion 2024-04-01 2 sites Stand-aloneOther conditions: Renal Insufficiency, ChronicView official trial listing → -
Completed NCT NCT05417646
Impact of SGLT2 on Glucosuria in HNF1A-MODY
Not yet reported Steno Diabetes Center Copenhagen 21 participants Est. completion 2023-06-14 1 siteType 2 diabetes Other conditions: Maturity-Onset Diabetes of the Young, Type 3View official trial listing → -
Completed NCT NCT05426525
Use of Empagliflozin to Treat Prediabetes
Not yet reported Oregon State University 60 participants Est. completion 2026-08-20 1 site Stand-alonePrediabetes Other conditions: Prediabetic State, Overweight and ObesityView official trial listing → -
Completed NCT NCT05465317
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
Boehringer Ingelheim 62197 participants Est. completion 2023-05-02 1 siteType 2 diabetesView official trial listing → -
Status unknown NCT NCT05477017
Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients
University of Milan 800 participants Est. completion 2023-03 1 siteOther conditions: Type2DiabetesView official trial listing → -
Completed NCT NCT05493371
Empagliflozin in Pulmonary Arterial Hypertension
Not yet reported Amsterdam UMC, location VUmc 8 participants Est. completion 2024-11-01 1 site Stand-aloneOther conditions: Idiopathic Pulmonary Arterial HypertensionView official trial listing → -
Completed NCT NCT05504226
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin
Not yet reported Handok Inc. 214 participants Est. completion 2024-06-18 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT05504239
Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin
Not yet reported Handok Inc. 235 participants Est. completion 2024-04-23 1 siteType 2 diabetesView official trial listing → -
Active, not recruiting NCT NCT05510115
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
Not yet reported University of Colorado, Denver 50 participants Est. completion 2026-08-01 1 site Stand-aloneOther conditions: Polycystic Kidney, Autosomal DominantView official trial listing → -
Status unknown NCT NCT05512130
Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy
Not yet reported Washington University School of Medicine 18 participants Est. completion 2023-06-30 1 site Stand-aloneOther conditions: EpilepsyView official trial listing → -
Status unknown NCT NCT05520684
Asymptomatic Bacteriuria, Urinalysis Abnormality at the Initiation of SGLT2 Inhibitors and UTI Risk
Trabzon Arakli Bayram Halil Public Hospital 120 participants Est. completion 2023-01-01 1 siteOther conditions: Type2diabetes, SGLT2 Inhibitor, Urinary Tract InfectionView official trial listing → -
Status unknown NCT NCT05545800
Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy
Not yet reported Xiangya Hospital of Central South University 78 participants Est. completion 2024-06-01 1 site Stand-aloneType 2 diabetesView official trial listing → -
Active, not recruiting NCT NCT05553938
Effects of Acute and Chronic Empagliflozin Heart Failure
Not yet reported Yale University 60 participants Est. completion 2026-08-14 2 sites Stand-aloneHeart failureView official trial listing → -
Status unknown NCT NCT05556044
Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction
Not yet reported Chinese University of Hong Kong 200 participants Est. completion 2024-05-31 1 siteHeart failureView official trial listing → -
Status unknown NCT NCT05580510
" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
Not yet reported, Not yet reported Instituto Nacional de Cardiologia Ignacio Chavez 160 participants Est. completion 2024-03-29 1 site Stand-aloneHeart failure Other conditions: Congenital Heart DiseaseView official trial listing → -
Status unknown NCT NCT05600387
Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Not yet reported Zhijun Sun 100 participants Est. completion 2025-10 1 site Stand-aloneHeart failureView official trial listing → -
Status unknown NCT NCT05605158
Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis
Not yet reported Tanta University 56 participants Est. completion 2024-11 1 siteOther conditions: Non Alcoholic SteatohepatitisView official trial listing → -
Status unknown NCT NCT05612269
SGLT2 Inhibitors and Reducing the Risk of Cancers Among Diabetics , an Observational Study
Ministry of Health, Saudi Arabia 200 participants Est. completion 2024-01-31 1 siteType 2 diabetes Other conditions: Cancer, Interleukin 6, SGLT2 InhibitorsView official trial listing → -
Completed NCT NCT05614115
Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD
Not yet reported University of Utah 62 participants Est. completion 2025-06-30 1 site Stand-aloneOther conditions: End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis, Diabetic, Non-diabetic, Kidney Dysfunction, Kidney Failure, HemodialysisView official trial listing → -
Completed NCT NCT05638880
Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease
Not yet reported Mostafa Bahaa 60 participants Est. completion 2025-12-20 1 site Stand-aloneOther conditions: Diabetic NephropathiesView official trial listing → -
Active, not recruiting NCT NCT05671991
Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease
Not yet reported Yale University 22 participants Est. completion 2026-12-31 1 site Stand-aloneOther conditions: End Stage Renal Disease on DialysisView official trial listing → -
Completed NCT NCT05681273
Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.
Not yet reported Chipscreen Biosciences, Ltd. 48 participants Est. completion 2023-03-21 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT05757791
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
Not yet reported NYU Langone Health 20 participants Est. completion 2026-06-06 1 site Stand-aloneOther conditions: Major Depressive DisorderView official trial listing → -
Status unknown NCT NCT05776043
Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
Not yet reported Medical University of Warsaw 1364 participants Est. completion 2025-12-31 1 siteHeart failureView official trial listing → -
Completed NCT NCT05822674
Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio
University of Diyala 80 participants Est. completion 2023-02-01 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT05823870
This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component(Empagliflozin and Metformin) in Healthy Adult Volunteers in Fast Condition.
Not yet reported Dong Wha Pharmaceutical Co. Ltd. 32 participants Est. completion 2023-03-20 1 site Stand-aloneOther conditions: Healthy SubjectsView official trial listing → -
Status unknown NCT NCT05823883
This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component in Healthy Adult Volunteers in Fed Condition.
Not yet reported Dong Wha Pharmaceutical Co. Ltd. 30 participants Est. completion 2023-08 1 site Stand-aloneOther conditions: DW6014View official trial listing → -
Completed NCT NCT05857085
Novel Therapeutics and Endothelial Dysfunction in T1DM Patients
Not yet reported General and Teaching Hospital Celje 90 participants Est. completion 2023-04-20 1 siteOther conditions: Endothelial Dysfunction, Diabetes Mellitus, Type 1, Biomarkers, Endothelial Progenitor Cells, SGLT 2 Inhibitors, Incretins, Glucose Excursions, FMD, FPF, Arterial StiffnessView official trial listing → -
Withdrawn NCT NCT05885074
Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors
Not yet reported University of Alabama at Birmingham Est. completion 2027-06-30 1 site Stand-aloneOther conditions: Obesity, Weight LossView official trial listing → -
Status unknown NCT NCT05905965
Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment
Not yet reported Collegium Medicum w Bydgoszczy 200 participants Est. completion 2026-03-31 1 site Stand-aloneMetabolic syndromeView official trial listing → -
Completed NCT NCT05911724
Association Between Inflammatory Biomarkers in CVD Patients on Empagliflozin.
Damanhour University 180 participants Est. completion 2024-09-30 1 siteHeart failure Other conditions: Stable AnginaView official trial listing → -
Status unknown NCT NCT05942963
Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD
Not yet reported Jinnah Postgraduate Medical Centre 240 participants Est. completion 2024-04 1 site Stand-aloneOther conditions: Non-Alcoholic Fatty Liver Disease, Type2diabetesView official trial listing → -
Completed NCT NCT05946148
Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)
National and Kapodistrian University of Athens 78 participants Est. completion 2021-05-31 1 siteOther conditions: Non-Alcoholic Fatty Liver Disease, Liver SteatosisView official trial listing → -
Completed NCT NCT05956522
Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects
Not yet reported The Affiliated Hospital of Qingdao University 106 participants Est. completion 2023-01-13 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Withdrawn NCT NCT05960617
Efficacy and Safety of Empagliflozin in GSD-Ib Patients
Not yet reported Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Est. completion 2024-12-31 1 site Stand-aloneOther conditions: Glycogen Storage Disease Type IBView official trial listing → -
Completed NCT NCT05967156
Empagliflozin in Heart Failure Dialysis Patients
Not yet reported Shahid Beheshti University of Medical Sciences 30 participants Est. completion 2025-06-03 1 site Stand-aloneHeart failure Other conditions: HemodialysisView official trial listing → -
Completed NCT NCT05977465
Empagliflozin in Treatment of Peripheral Diabetic Neuropathy
Not yet reported, Not yet reported Tanta University 50 participants Est. completion 2023-08-03 1 site Stand-aloneOther conditions: Diabetic Neuropathy PeripheralView official trial listing → -
Completed NCT NCT05989503
Initiation of ARNi and SGLT2i in Patients With HFrEF
Not yet reported Universidade do Porto 62 participants Est. completion 2025-07-31 5 sitesHeart failureView official trial listing → -
Status unknown NCT NCT06012266
Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale
Not yet reported Centre Hospitalier Universitaire Vaudois 12 participants Est. completion 2025-08 3 sitesHeart failureView official trial listing → -
Status unknown NCT NCT06021145
Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes
Not yet reported McGill University Health Centre/Research Institute of the McGill University Health Centre 46 participants Est. completion 2025-05 1 site Stand-aloneOther conditions: Type 1 DiabetesView official trial listing → -
Status unknown NCT NCT06046612
Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
Not yet reported Maastricht University Medical Center 48 participants Est. completion 2025-02-13 1 site Stand-aloneHeart failure Other conditions: Microvascular DysfunctionView official trial listing → -
Completed NCT NCT06065280
Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients
Not yet reported Damanhour University 80 participants Est. completion 2024-12-30 1 site Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT06085703
Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial
Not yet reported The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 24 participants Est. completion 2025-06-30 1 site Stand-aloneType 2 diabetes Other conditions: Mild Cognitive ImpairmentView official trial listing → -
Completed NCT NCT06094920
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
Not yet reported University Medical Center Groningen 12 participants Est. completion 2025-09-24 1 siteType 2 diabetesChronic kidney disease Other conditions: Diabetes Mellitus, Diabetes, Diabetes Complications, AlbuminuriaView official trial listing → -
Status unknown NCT NCT06098625
Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus
Not yet reported Medanta, The Medicity, India 200 participants Est. completion 2025-12-01 Stand-aloneOther conditions: Diabetes Mellitus, Kidney Transplant; ComplicationsView official trial listing → -
Status unknown NCT NCT06103279
Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin
Not yet reported, Not yet reported Ain Shams University 40 participants Est. completion 2024-08 Stand-aloneOther conditions: CancerView official trial listing → -
Completed NCT NCT06117137
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
Not yet reported Sohag University 150 participants Est. completion 2026-04-03 1 site Stand-aloneOther conditions: Fatty Liver, NonalcoholicView official trial listing → -
Terminated NCT NCT06124924
SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot
Not yet reported University of Minnesota 1 participants Est. completion 2024-08-16 1 site Stand-aloneOther conditions: Acute Kidney InjuryView official trial listing → -
Status unknown NCT NCT06124937
Empagliflozin to Prevent Post-Operative Atrial Fibrillation
Not yet reported Rajaie Cardiovascular Medical and Research Center 492 participants Est. completion 2024-12-30 2 sites Stand-aloneOther conditions: Post-operative Atrial Fibrillation, CABGView official trial listing → -
Status unknown NCT NCT06128096
The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD)
Clinical Research Centre, Malaysia 360 participants Est. completion 2024-12-31 1 siteCardiovascular diseaseView official trial listing → -
Completed NCT NCT06140108
Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity
Not yet reported, Not yet reported SINA Health Education and Welfare Trust 70 participants Est. completion 2024-06-30 1 site Stand-aloneOther conditions: Polycystic Ovary Syndrome, Weight Gain, HbA1cView official trial listing → -
Completed NCT NCT06145360
Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient
Not yet reported SINA Health Education and Welfare Trust 150 participants Est. completion 2024-03-01 1 site Stand-aloneType 2 diabetes Other conditions: Glucose Metabolism Disorders, Hypoglycemic Agents, EmpagliflozinView official trial listing → -
Active, not recruiting NCT NCT06149793
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
Not yet reported, Not yet reported University of Minnesota 8 participants Est. completion 2026-12-31 1 siteOther conditions: Cystic Fibrosis-related Diabetes, Cystic FibrosisView official trial listing → -
Completed NCT NCT06171802
EMPagliflozin After Aortic Valve Replacement
Not yet reported Rigshospitalet, Denmark 206 participants Est. completion 2026-05-18 1 siteOther conditions: Aortic Valve StenosisView official trial listing → -
Status unknown NCT NCT06187493
Treatment of Patients With Diabetic Kidney Disease
Not yet reported Assiut University 70 participants Est. completion 2025-12-31Chronic kidney diseaseView official trial listing → -
Status unknown NCT NCT06201000
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients
October 6 University 282 participants Est. completion 2024-09-01 1 siteHeart failure Other conditions: Genetic PolymorphismsView official trial listing → -
Status unknown NCT NCT06232239
Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg
Not yet reported Bio-innova Co., Ltd 26 participants Est. completion 2024-04-19 Stand-aloneOther conditions: Healthy SubjectsView official trial listing → -
Withdrawn NCT NCT06280976
Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)
Not yet reported University of Louisville Est. completion 2025-01-01 1 site Stand-aloneCardiovascular disease Other conditions: Atherosclerosis, Heart AttackView official trial listing → -
Status unknown NCT NCT06284850
Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels
Aristotle University Of Thessaloniki 40 participants Est. completion 2025-11 1 siteOther conditions: Hematocrit Change, Cardiovascular Prevention, Empagliflozin, SGLT2-Inhibitors, Tissue OxygenationView official trial listing → -
Completed NCT NCT06287073
JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
Boehringer Ingelheim 299 participants Est. completion 2025-04-30 12 sitesOther conditions: Kidney Disease, ChronicView official trial listing → -
Status unknown NCT NCT06308679
A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions
Not yet reported Pharma Nueva 28 participants Est. completion 2024-06-07 Stand-aloneOther conditions: Healthy VollunteerView official trial listing → -
Completed NCT NCT06313008
Empagliflozin Versus Vildagliptin in CAD Patients With T2DM
Not yet reported Damanhour University 120 participants Est. completion 2024-10-10 1 site Stand-aloneCardiovascular diseaseType 2 diabetesView official trial listing → -
Status unknown NCT NCT06337409
Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers
Not yet reported International Bio service 30 participants Est. completion 2024-07-13 Stand-aloneOther conditions: Healthy VolunteerView official trial listing → -
Completed NCT NCT06339788
Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
Not yet reported Handok Inc. 40 participants Est. completion 2024-06-12 1 siteOther conditions: Healthy VolunteersView official trial listing → -
Completed NCT NCT06350903
Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging
Not yet reported Matthieu Pelletier-Galarneau, MD MSc 16 participants Est. completion 2024-11-01 1 siteOther conditions: Myocardial SuppressionView official trial listing → -
Completed NCT NCT06370247
First-time Usage of SGLT2 Inhibitors in Type 2 Diabetic Patients Who Are Fasting During Ramadan: Safety and Efficacy
Not yet reported Sohag University 60 participants Est. completion 2023-09-25 1 siteType 2 diabetes Other conditions: SGLT2 Inhibitors, First Time Use, Fasting in RamadanView official trial listing → -
Active, not recruiting NCT NCT06391450
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
Not yet reported Hannover Medical School 44 participants Est. completion 2027-05 1 site Stand-aloneOther conditions: Autosomal Dominant Polycystic KidneyView official trial listing → -
Completed NCT NCT06450262
Bioequivalence Study to Compare Empagliflozin/ Metformin HCl 12.5mg/1000mg Film-coated Tablets
Not yet reported Humanis Saglık Anonim Sirketi 36 participants Est. completion 2024-03-05 1 site Stand-aloneOther conditions: Type2diabetesView official trial listing → -
Completed NCT NCT06469645
The Role of SGLT2i in Management of Moderate AS
Not yet reported, Not yet reported University of East Anglia 104 participants Est. completion 2026-07-24 1 site Stand-aloneOther conditions: Moderate Aortic Valve StenosisView official trial listing → -
Status unknown NCT NCT06492655
To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers
Not yet reported Chong Kun Dang Pharmaceutical 28 participants Est. completion 2024-08-08Type 2 diabetesView official trial listing → -
Status unknown NCT NCT06503601
The Impact of Genetic Polymorphism on the Echocardiographic Parameters and Cardiac Fibrosis Markers in Response to Empagliflozin Treatment Among Patients With Heart Failure
Ain Shams University 92 participants Est. completion 2025-10-01 1 siteHeart failureView official trial listing → -
Enrolling by invitation NCT NCT06519448
Reducing Non-Alcoholic Steatohepatitis
Not yet reported Military University Hospital, Prague 30 participants Est. completion 2027-12-31 1 site Stand-aloneType 2 diabetes Other conditions: Non-alcoholic Steatohepatitis, Liver Diseases, Fibrosis, LiverView official trial listing → -
Active, not recruiting NCT NCT06527846
Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease
Boehringer Ingelheim 1024 participants Est. completion 2027-03-31 1 siteOther conditions: Kidney Disease, ChronicView official trial listing → -
Completed NCT NCT06571591
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Not yet reported Celltrion 606 participants Est. completion 2026-05-04 1 siteType 2 diabetesView official trial listing → -
Status unknown NCT NCT06578676
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
Not yet reported Hyundai Pharm 56 participants Est. completion 2024-11-30 1 site Stand-aloneType 2 diabetes Other conditions: DyslipidemiasView official trial listing → -
Completed NCT NCT06632561
Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus
Not yet reported Ashraf Wasfy Beshay Aziz 74 participants Est. completion 2022-03-14 1 site Stand-aloneHeart failureView official trial listing → -
Not yet recruiting NCT NCT06641128
The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate
Not yet reported Tanta University 44 participants Est. completion 2025-04-10 1 siteOther conditions: Rheumatoid Arthritis (RA), Methotrexate Induced Nephrotoxicity, Methotrexate Adverse ReactionView official trial listing → -
Not yet recruiting NCT NCT06643442
Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age
Not yet reported Sebastiano Lava 12 participants Est. completion 2027-03-31 1 site Stand-aloneOther conditions: DMD-associated Dilated CardiomyopathyView official trial listing → -
Not yet recruiting NCT NCT06668753
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
Assiut University 114 participants Est. completion 2027-07-30MASLDChronic kidney diseaseView official trial listing → -
Active, not recruiting NCT NCT06683053
Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department
Not yet reported Conrado Roberto Hoffmann Filho 90 participants Est. completion 2025-02-28 1 site Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT06697353
An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
Bayer 4936 participants Est. completion 2025-09-19 1 siteHeart failureView official trial listing → -
Completed NCT NCT06759922
Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes
Not yet reported Bahria University 172 participants Est. completion 2025-06-30 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT06762314
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
Not yet reported Mostafa Bahaa 114 participants Est. completion 2026-01-20 1 siteOther conditions: DiabetesView official trial listing → -
Completed NCT NCT06792968
Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
Not yet reported Gedeon Richter Plc. 64 participants Est. completion 2025-04-08 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT06797115
Hydroxyl Free Radical Associated Effects of SGLT-2 Inhibitors in Type 2 Diabetes
University of Pecs 40 participants Est. completion 2024-06-30 1 siteType 2 diabetesView official trial listing → -
Terminated NCT NCT06818305
Efficacy and Safety of Finerenone and Empagliflozin in Delaying Renal Function Progression After Radical Nephrectomy in High-Risk CKD Patients: A Multicenter RCT
Not yet reported Jinling Hospital, China 10 participants Est. completion 2025-10-01 1 site Stand-aloneChronic kidney disease Other conditions: Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), NephrectomyView official trial listing → -
Completed NCT NCT06823856
Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)
Not yet reported Gedeon Richter Plc. 64 participants Est. completion 2025-05-21 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT06825156
Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors
Not yet reported Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 60 participants Est. completion 2023-05-26 1 site Stand-aloneOther conditions: Acute Kidney InjuryView official trial listing → -
Completed NCT NCT06828731
Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes
Not yet reported Charles George VA Medical Center 60 participants Est. completion 2025-09-05 1 site Stand-alonePrediabetesView official trial listing → -
Terminated NCT NCT06844669
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
Not yet reported Washington University School of Medicine 7 participants Est. completion 2026-05-07 1 site Stand-aloneOther conditions: HER2-positive Breast Cancer, HER2+ Breast CancerView official trial listing → -
Completed NCT NCT06851962
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Not yet reported Fundación para la Investigación del Hospital Clínico de Valencia 92 participants Est. completion 2026-06-30 3 sites Added to GLP-1Type 2 diabetesView official trial listing → -
Completed NCT NCT06889350
Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
Not yet reported Handok Inc. 40 participants Est. completion 2025-05-07 1 siteOther conditions: Healthy VolunteersView official trial listing → -
Completed NCT NCT06915870
Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment
Not yet reported Fatima Maqsood 108 participants Est. completion 2025-01-13 1 site Stand-aloneHeart failure Other conditions: Diabetes MellitusView official trial listing → -
Completed NCT NCT06926660
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
Not yet reported Boehringer Ingelheim 492 participants Est. completion 2026-08-14 157 sites Stand-aloneChronic kidney diseaseView official trial listing → -
Completed NCT NCT06932159
Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets
Not yet reported Humanis Saglık Anonim Sirketi 40 participants Est. completion 2025-04-08 1 site Stand-aloneType 2 diabetesView official trial listing → -
Active, not recruiting NCT NCT06933355
Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension
Not yet reported Odense University Hospital 8 participants Est. completion 2026-06-01 1 siteOther conditions: Kidney Transplantation Recipients, Magnetic Resonance Imaging (MRI), Sodium-Glucose Transporter 2 Inhibitors, Non-Diabetic Patients, Randomized Controlled Trial, Placebo Control DesignView official trial listing → -
Completed NCT NCT06952231
Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus
Not yet reported University of Lahore 50 participants Est. completion 2025-01-05 1 siteOther conditions: Diabetes MellitusView official trial listing → -
Completed NCT NCT06962826
A Study in Healthy People to Test How Empagliflozin is Taken up in the Body When Taken as a Whole Tablet or Dissolved in Water and Mixed With Food
Not yet reported Boehringer Ingelheim 14 participants Est. completion 2025-09-12 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Active, not recruiting NCT NCT07003191
Metformin Hydrochloride and Empagliflozin Tablets in the Treatment of Type 2 Diabetes
Sun Yat-sen University 2600 participants Est. completion 2025-12-31 1 siteType 2 diabetesView official trial listing → -
Not yet recruiting NCT NCT07027969
Metabolic Surgery for Atrial Fibrillation Elimination
Not yet reported Ali Aminian 100 participants Est. completion 2030-03-31 1 siteOther conditions: Atrial Fibrillation, Obesity and Obesity-related Medical ConditionsView official trial listing → -
Completed NCT NCT07035457
A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together
Not yet reported Boehringer Ingelheim 15 participants Est. completion 2025-08-15 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Completed NCT NCT07039890
To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.
Not yet reported Humanis Saglık Anonim Sirketi 40 participants Est. completion 2025-06-05 1 site Stand-aloneType 2 diabetesView official trial listing → -
Not yet recruiting NCT NCT07044700
Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction
Boehringer Ingelheim 5000 participants Est. completion 2028-12-31 1 siteHeart failureView official trial listing → -
Not yet recruiting NCT NCT07047508
Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction
Boehringer Ingelheim 3000 participants Est. completion 2028-12-31Heart failure Other conditions: Preserved Ejection FractionView official trial listing → -
Not yet recruiting NCT NCT07060417
Vascular Effects of SGLT2i in Non-diabetic CKD
Not yet reported VA Office of Research and Development 52 participants Est. completion 2029-09-30 1 siteChronic kidney diseaseView official trial listing → -
Enrolling by invitation NCT NCT07065357
Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor
Not yet reported The University of Hong Kong 160 participants Est. completion 2026-12 1 site Stand-aloneMetabolic syndromeView official trial listing → -
Completed NCT NCT07076056
Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2
Not yet reported Daewon Pharmaceutical Co., Ltd. 230 participants Est. completion 2024-06-19 1 site Stand-aloneType 2 diabetesView official trial listing → -
Not yet recruiting NCT NCT07105917
SLGT2i for Neuroprotection in Patients With Acute Ischemic Stroke
Not yet reported Second Affiliated Hospital, Zhejiang University, School of Medicine 1050 participants Est. completion 2026-11-01 Stand-aloneCardiovascular diseaseView official trial listing → -
Completed NCT NCT07112274
Empagliflozin on Patients With Preserved Heart Failure
Not yet reported Damanhour University 50 participants Est. completion 2025-07-30 1 site Stand-aloneHeart failureView official trial listing → -
Completed NCT NCT07120828
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity
Not yet reported Erbil Polytechnic University 260 participants Est. completion 2026-03-15 1 site Stand-aloneType 2 diabetes Other conditions: Obese Diabetics, Obese Patients (BMI ≥ 30 kg/m²)View official trial listing → -
Completed NCT NCT07128654
A Bioequivalence Study of CT-L02 Compared to Co-administration (CTL0201 and CTL0202) in Healthy Volunteers
Not yet reported Celltrion 40 participants Est. completion 2025-10-26 1 siteOther conditions: HealthyView official trial listing → -
Completed NCT NCT07133399
A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood
Not yet reported Boehringer Ingelheim 32 participants Est. completion 2025-10-22 1 site Stand-aloneOther conditions: HealthyView official trial listing → -
Not yet recruiting NCT NCT07155694
Role of Finerenone in African American Veterans With Diabetic Kidney Disease
Not yet reported Washington D.C. Veterans Affairs Medical Center 30 participants Est. completion 2027-08 1 siteChronic kidney diseaseView official trial listing → -
Not yet recruiting NCT NCT07180745
Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease
Not yet reported Badr University 400 participants Est. completion 2026-03-01 1 siteMASLDMASHView official trial listing → -
Not yet recruiting NCT NCT07186153
Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling in Diabetic Patients
Assiut University 100 participants Est. completion 2026-11-01Other conditions: SGLT 2 InhibitorsView official trial listing → -
Active, not recruiting NCT NCT07188545
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Ohio State University 23280000 participants Est. completion 2029-06-30 1 siteMetabolic syndromeView official trial listing → -
Active, not recruiting NCT NCT07198191
SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study
Yonsei University 200000 participants Est. completion 2026-08-30 1 siteCardiovascular diseaseType 2 diabetesView official trial listing → -
Completed NCT NCT07213895
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets
Not yet reported Humanis Saglık Anonim Sirketi 14 participants Est. completion 2025-09-18 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT07266766
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
Not yet reported Humanis Saglık Anonim Sirketi 40 participants Est. completion 2025-10-06 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT07269197
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes
Josip Juraj Strossmayer University of Osijek 67 participants Est. completion 2025-10-10 1 siteType 2 diabetes Other conditions: Non-Alcoholic Fatty Liver DiseaseView official trial listing → -
Active, not recruiting NCT NCT07325435
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
Not yet reported MaryAnn Banerji 60 participants Est. completion 2028-06-30 1 siteType 2 diabetesView official trial listing → -
Not yet recruiting NCT NCT07331220
Pulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection Fraction
Not yet reported Nanjing First Hospital, Nanjing Medical University 310 participants Est. completion 2028-12-30 1 site Stand-aloneHeart failureView official trial listing → -
Not yet recruiting NCT NCT07334145
Effect of SGLT2 Inhibitors on Anemic CKD Patients
Sohag University 60 participants Est. completion 2026-09-01 1 siteChronic kidney diseaseView official trial listing → -
Not yet recruiting NCT NCT07348484
Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors
Instituto de Investigación Biomédica de Salamanca 300 participants Est. completion 2028-03 1 siteChronic kidney diseaseView official trial listing → -
Completed NCT NCT07363707
A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.
Not yet reported Beni-Suef University 108 participants Est. completion 2024-03-01 1 siteMASLDView official trial listing → -
Completed NCT NCT07367555
Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients
Not yet reported Ariba Shafiq 360 participants Est. completion 2025-03-31 1 site Stand-aloneOther conditions: Diabete MellitusView official trial listing → -
Completed NCT NCT07372118
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast Condition
Not yet reported Humanis Saglık Anonim Sirketi 32 participants Est. completion 2026-01-07 1 site Stand-aloneType 2 diabetesView official trial listing → -
Completed NCT NCT07379788
ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling
Not yet reported Rehab Werida 180 participants Est. completion 2026-03-01 1 siteHeart failureView official trial listing → -
Not yet recruiting NCT NCT07391267
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.
Not yet reported Institute of Liver and Biliary Sciences, India 90 participants Est. completion 2028-12-31 1 site Added to GLP-1Chronic kidney disease Other conditions: MAFLDView official trial listing → -
Active, not recruiting NCT NCT07450417
Effect of Early Empagliflozin Initiation in Cardiogenic Shock.
Central Hospital, Nancy, France 418 participants Est. completion 2026-04 1 siteOther conditions: Cardiogenic ShockView official trial listing → -
Enrolling by invitation NCT NCT07452913
Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes
Not yet reported Bahria University 110 participants Est. completion 2026-06-30 1 siteType 2 diabetesView official trial listing → -
Active, not recruiting NCT NCT07478575
Effects of SGLT2 Inhibitors on Erythropoiesis in Heart Failure
University Medical Centre Ljubljana 85 participants Est. completion 2026-12-31 1 siteHeart failure Other conditions: Anemia, Renal InsufficiencyView official trial listing → -
Completed NCT NCT07479108
Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions
Not yet reported ADIUM 32 participants Est. completion 2024-12-11 1 site Stand-aloneOther conditions: BioequivalanceView official trial listing → -
Completed NCT NCT07531108
Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes
Not yet reported Hawler Medical University 186 participants Est. completion 2025-11-27 1 siteType 2 diabetesView official trial listing → -
Not yet recruiting NCT NCT07533747
PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction
Not yet reported King's College London 100 participants Est. completion 2031-05 Stand-aloneOther conditions: Coronary Microvascular Dysfunction (CMD)View official trial listing → -
Completed NCT NCT07541456
Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 Diabetes
Not yet reported Dr. Zarmina Younes 300 participants Est. completion 2025-11-08 1 site Stand-aloneType 2 diabetes Other conditions: HypertensionView official trial listing → -
Not yet recruiting NCT NCT07547878
Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
Not yet reported Baylor Research Institute 64 participants Est. completion 2029-03-31 1 siteChronic kidney diseaseType 2 diabetesView official trial listing → -
Completed NCT NCT07556094
Empagliflozin and CPAP in Adults With Heart Failure and Obstructive Sleep Apnea.
Not yet reported Medical University of Bialystok 70 participants Est. completion 2025-05-09 1 site Stand-aloneObstructive sleep apneaHeart failure Other conditions: Sleep Apnea Syndrome, ObstructiveView official trial listing → -
Completed NCT NCT07563647
Association Between Diastolic Dysfunction and Erectile Dysfunction and the Effect of Tadalafil and SGLT2 Inhibitors on Them in Men With Metabolic Syndrome
Not yet reported Kafrelsheikh University 60 participants Est. completion 2026-03-17 1 site Stand-aloneMetabolic syndrome Other conditions: Erectile Dysfunction, Left Ventricular Diastolic DysfunctionView official trial listing → -
Active, not recruiting NCT NCT07586371
Proteinuria in Normotensive Diabetic Patients: ARBs Alone or in Combination of SGLT2i
Not yet reported, Not yet reported Dr Mudassar Saeed Pansota 60 participants Est. completion 2026-08-05 1 site Stand-aloneOther conditions: Proteinuria, Diabetes (DM)View official trial listing → -
Completed NCT NCT07591077
SGLT2 Adjunct in T1D
Not yet reported, Not yet reported Ain Shams University 86 participants Est. completion 2026-02-20 1 siteOther conditions: Type 1 Diabetes, Nephropathy, DiabeticView official trial listing → -
Completed NCT NCT07599293
Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data
Brigham and Women's Hospital 39614 participants Est. completion 2026-06-19 1 siteHeart failureType 2 diabetesView official trial listing → -
Completed NCT NCT07599345
Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims Data
Brigham and Women's Hospital 23955 participants Est. completion 2026-06-15 1 siteHeart failureView official trial listing → -
Completed NCT NCT07633015
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 5 mg / 850 mg Tablets Under Fed Conditions.
Not yet reported ADIUM 42 participants Est. completion 2025-04-29 1 site Stand-aloneOther conditions: Bioequivalence Study in Healthy SubjectsView official trial listing → -
Completed NCT NCT07633041
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 1000 mg Tablets Under Fed Conditions.
Not yet reported ADIUM 42 participants Est. completion 2025-04-04 1 site Stand-aloneOther conditions: Bioequivalence Study in Healthy SubjectsView official trial listing → -
Completed NCT NCT07633054
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Empagliflozin/Metformin in 12.5 mg / 500 mg Tablets Under Fed Conditions.
Not yet reported ADIUM 42 participants Est. completion 2025-11-24 1 site Stand-aloneOther conditions: Bioequivalence Study in Healthy SubjectsView official trial listing → -
Not yet recruiting NCT NCT07635953
New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes
Not yet reported Sun Yat-sen University 296 participants Est. completion 2031-07-01 1 site Stand-aloneOther conditions: Diabetes MellitusView official trial listing → -
Not yet recruiting NCT NCT07678151
Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled Trial
Not yet reported Heart Health Research Center 260 participants Est. completion 2027-08-31 2 sites Stand-aloneOther conditions: Hypertension (HTN)View official trial listing → -
Completed NCT NCT07691203
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets
Not yet reported Humanis Saglık Anonim Sirketi 36 participants Est. completion 2026-07-01 1 site Stand-aloneType 2 diabetesCardiovascular diseaseView official trial listing → -
Completed NCT NCT07694115
Bioequivalence Study to Compare Empagliflozin/ Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
Not yet reported Humanis Saglık Anonim Sirketi 40 participants Est. completion 2026-07-01 1 site Stand-aloneType 2 diabetesView official trial listing → -
Active, not recruiting NCT NCT07694596
SGLT2 Inhibitors and Cognitive Function in Adults With Type 2 Diabetes (SaveMinD)
Not yet reported University of Primorska 200 participants Est. completion 2028-04-20 1 site Stand-aloneType 2 diabetes Other conditions: Cognitive DysfunctionView official trial listing → -
Not yet recruiting NCT NCT07728318
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Not yet reported Akhtar Saeed Medical and Dental College 52 participants Est. completion 2027-05-12Type 2 diabetesView official trial listing → -
Not yet recruiting NCT NCT07749014
Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients
Not yet reported Rehman Medical Institute - RMI 480 participants Est. completion 2027-09-30 1 site Stand-aloneCardiovascular diseaseView official trial listing → -
Not yet recruiting NCT NCT07756294
Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease
Not yet reported Wake Forest University Health Sciences 30 participants Est. completion 2028-04 1 site Stand-aloneOther conditions: Alzheimer DiseaseView official trial listing → -
Not yet recruiting NCT NCT07766109
Discontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac Surgery
Not yet reported University Hospital, Toulouse 434 participants Est. completion 2029-01 1 siteHeart failure Other conditions: Cardiac SurgeryView official trial listing → -
Not yet recruiting NCT NCT07775846
QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy
Not yet reported Huijie Zhang 820 participants Est. completion 2029-06-30 1 site Stand-aloneChronic kidney diseaseView official trial listing → -
Not yet recruiting NCT NCT07799441
Neurovascular Effects of Empagliflozin
Not yet reported Kanokwan Bunsawat 100 participants Est. completion 2029-01 1 site Stand-aloneOther conditions: Blood Pressure, Endothelial DysfunctionView official trial listing → -
Not yet recruiting NCT NCT07815808
Cardioprotective Effect of Empagliflozin in Breast Cancer Patients
Not yet reported Tanta University 150 participants Est. completion 2028-12-31 1 siteOther conditions: Empgliflozin Cardioprotective EffectView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Also known as: Empagliflozin, Synjardy, JARDIANCE
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.